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Abstract 
Novel connections between DNA replication, telomere homeostasis and the DNA 
damage response revealed by a genome-wide screen for TEL 11A TM interactions in 
Saccharomyces cerevisiae 
Brian D. Piening 
Chair of Supervisory Committee: 
Professor Daniel E. Gottschling 
Department of Genome Sciences 
Tel1 p is the budding yeast ortholog of the mammalian tumor suppressor and 
DNA damage response (DDR) kinase ATM. However, te/1-lJ. cells, unlike ATM-deficient 
cells, do not exhibit sensitivity to DNA damaging agents, but do display shortened (but 
stably maintained) telomere lengths. Neither the extent to which ATMIT el1 p functions in 
the DDR nor the mechanism by which ATMITel1 p contributes to telomere metabolism is 
well-understood. In this dissertation, I present our large-scale transcriptional profiling of 
normal and ATM-deficient lymphoblast cell lines in response to ionizing radiation (IR). 
From these results, we make the surprising observation that A TM-deficient cells exhibit 
no significant defects in IR-induced gene expression, which along with work from others 
suggests that significant redundancy exists in the DNA damage response, and may be 
an explanation for the relative DNA damage insensitivity in te/1-lJ. yeast cells. To 
address this question, I performed a comprehensive genome-wide screen for genetic 
interactions with te/1-lJ. that cause sensitivity to MMS and/or ionizing radiation, along 
with follow-up characterizations of the 13 interactions yielded by this screen. 
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Surprisingly, many of the teI1-11 interactions that confer DNA damage sensitivity also 
exacerbate the short telomere phenotype, suggesting a connection between these two 
phenomena. Restoration of normal telomere length in the teI1-11 xxx-11 mutants results 
in only minor suppression of the DNA damage sensitivity, demonstrating that the 
sensitivity of these mutants must also involve mechanisms independent of telomere 
length. In support of a model for increased replication stress in the teI1-11 xxx-11 
mutants, I show that depletion of dNTP pools through pre-treatment with hydroxyurea 
renders teI1-11 cells (but not wild-type) MMS-sensitive, demonstrating that under certain 
conditions, Tel1 p does indeed playa critical role in the DDR. 
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CHAPT R 1: Introduction 
ATM: spearheading the DNA damage response 
The ATM tumor suppressor kinase is a major signaling component of the DNA 
damage response (DDR) pathway, and patients with homozygous A TM mutations are 
afflicted with the cancer-prone disorder Ataxia Telangiectasia (AT) (SAVITSKY et al. 1995; 
SHILOH 2003). It is estimated that as much as 3% of the population carry a mutant ATM 
allele (SWIFT et al. 1986), and carriers are at an elevated risk of developing breast cancer 
(RENWICK et al. 2006; THOMPSON et al. 2005). ATM frequently undergoes somatic 
mutation in cancer, and based on estimates of positive selection pressure, these 
mutations are thought to drive tumorigenesis (GREENMAN et al. 2007). A TM-deficient cell 
lines are sensitive to DNA damage, exhibit pronounced checkpoint and double-strand 
break (DSB) repair defects (KASTAN et al. 1992; KUHNE et al. 2004; PAINTER and YOUNG 
1980) and exhibit significantly reduced phosphorylation levels of DDR targets (CAN MAN et 
al. 1998). Cells from AT patients exhibit accelerated telomere shortening (METCALFE et al. 
1996) and ATM is thought to playa role in telomere length regulation through interactions 
with telomere binding proteins (Wu et al. 2007). 
In the absence of DNA damage, ATM exists in the cell as an inactive dimer 
(BAKKEN 1ST and KASTAN 2003). Following the generation of DSBs, ATM is recruited to 
sites of DNA damage by the Mre11-Rad50-Nbs1 DNA end-binding complex and its kinase 
function is activated (LEE and PAULL 2004; UZIEL et al. 2003). This activation requires 
ATM acetylation at K3016 by the histone acetyltransferase and tumor suppressor Tip60 
(SUN et al. 2005; SUN et al. 2010; SUN et al. 2007). Following acetylation, ATM activation 
also requires autophosphorylation at multiple sites and monomerization (BAKKENIST and 
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KASTAN 2003; KOZLOV et al. 2006). Activated ATM then initiates an incredibly complex 
signaling cascade involving numerous targets in the coordination of checkpoint activation 
and DNA repair initiation (LAVIN 2008; SHILOH 2003). Our knowledge of the myriad ways 
by which ATM influences the DDR are simplistic at best, and in all likelihood the coming 
years will provide an immense increase in novel connections between ATM and diverse 
cellular mechanisms. As an example, work in the past few years has shown that in 
response to oxidative stress, an alternative form of active ATM is generated through the 
formation of a disulfide bridge targeting C2991; this activation does not require the MRN 
complex nor the presence of DNA DSBs (Guo et al. 201 Oa; Guo et al. 2010b). Moreover, 
recent work by Kastan and colleagues has shown that ATM is recruited to dysfunctional 
mitochondria and loss of ATM is associated with an increase in mitochondrial ROS 
through a defect in targeting mitochondria for mitophagy (VALENTIN-VEGA and KASTAN 
2012; VALENTIN-VEGA et al. 2012). In all likelihood further characterization of these novel 
mechanisms will provide a significant increase in our understanding of how ATM prevents 
tu morigenesis. 
TEL 1 is the Saccharomyces cerevisiae A TM ortholog 
The Saccharomyces cerevisiae ortholog for mammalian A TM is TEL 1 (GREENWELL 
et al. 1995; MALLORY and PETES 2000; MORROW et al. 1995). Like ATM, Tel1 p is recruited 
to DSBs via an interaction with the Mre11-Rad50-Xrs2 DNA-binding complex (NAKADA et 
al. 2003) and Tel1 both facilitates efficient end-resection through an unknown mechanism 
and participates in phosphorylation of downstream DDR substrates (MANTIERO et al. 
2007). Following DSB resection, the related kinase Mec1 (ATR in mammals (CIMPRICH et 
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al. 1996)) recognizes RPA-coated ssDNA at ssDNA-dsDNA junctions via an interaction 
with Ddc2, and the DNA damage checkpoint is activated (PACIOTTI et al. 2000). The 
distinct sensing of double-strand and single-strand damaged DNA structures by Tel1 p 
and Mec1 p bears a striking resemblance to the different roles of their ATM and ATR 
counterparts in mammalian cells (LEE and PAULL 2007; Zou and ELLEDGE 2003). 
However, while the loss of MEC1 results in severe sensitivity to DNA damaging agents 
(WEINERT et al. 1994), Tel1p is not functionally required for checkpoint activation in 
response to intrachromosomal DSBs, and the loss of TEL 1 does not significantly sensitize 
cells to DNA damaging agents (GREENWELL et al. 1995; MORROW et a/. 1995). Despite 
this, a mec1 tel1 double mutant is more sensitive to DNA damage than the mec1 single 
mutant. These results demonstrate that although MEC1 plays the predominant role at 
intrachromosomal DSBs, TEL 1 does play some role in response to DNA damage in a 
mec1 background (MORROW et a/. 1995). 
TEL 11ATM functions in telomere maintenance 
Telomeres are comprised of repetitive, G-rich DNA elements (300-400 bp in yeast; 
multiple kilobases in mammals) and bound proteins that prevent these ends from being 
recognized as DNA double-strand breaks (DSBs) by the DNA damage response (DDR). 
In order to counteract the progressive end-shortening associated with semi-conservative 
DNA synthesis, eukaryotes employ the reverse transcriptase ribonucleoprotein complex 
telomerase, which synthesizes new repeat DNA at chromosomal ends (GREIDER and 
BLACKBURN 1985). In most human tissues however, telomerase is not expressed and 
progressive telomere shortening confers a limit to replicative life span, termed the Hayflick 
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limit (HAYFLICK and MOORHEAD 1961); this is thought to serve as an antitumor mechanism 
(HANAHAN and WEINBERG 2000). However, cells that have entered replicative senescence 
due to excessive telomere shortening can in rare cases escape senescence and gain the 
ability to maintain telomeres via recombination, in a process dubbed Alternative 
Lengthening of Telomeres (AL T) (LUNDBLAD and BLACKBURN 1993; TENG and ZAKIAN 
1999). 
While Mec1p appears to be the primary responder to DNA damage (with Tel1p 
functioning in a back-up role), their respective roles are reversed at telomeres. In 
Saccharomyces cerevisiae, the telomerase enzyme preferentially associates with short 
telomeres for elongation through an interaction with Cdc13, and this preferential 
association is dependent on TEL 1 and the MRX complex (SABOURIN et al. 2007). MRX 
recruits Tel1 p to DNA ends (FUKUNAGA et al. 2011), at which Tel1 p phosphorylates one 
or more substrates to facilitate telomerase recruitment by Cdc13 via an as yet poorly 
understood mechanism (GAO et al. 2010; MARTINA et al. 2012). tel1 mutant cells exhibit a 
decreased frequency of telomere elongation events and decreased telomerase 
processivity at telomeres (ARNERIC and LINGNER 2007; CHANG et al. 2007) that leads to 
progressive telomere shortening (GREENWELL et al. 1995; MALLORY and PETES 2000). 
Telomeres in tel1 cells are shortened but are stably maintained; this depends on MEC1 
(RITCHIE et al. 1999). Telomere erosion in a mec1 tel1 mutant leads to aneuploidy, 
senescence, and cell death (CRAVEN et al. 2002; MCCULLEY and PETES 2010; VERNON et 
al. 2008). Despite the requirement for MEC1 in telomere homeostasis in the absence of 
TEL 1, Mec1 p is not detected at telomeres in wild-type or teI1-..1 cells, and the specific role 
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Mec1 p plays in facilitating telomere maintenance in the absence of TEL 1 is not yet 
understood (MCGEE et a/. 2010). 
Unanswered questions regarding the role(s) of ATM/TEL 1 
Proteomic analyses have recently revealed that the substrate network targeted by 
ATMfTel1 after DNA damage is vast. In a large scale screen of ATM/ATR substrates 
utilizing antibodies recognizing the characteristic -SQfTQ motif, Matsuoka et a/. 
described over 700 proteins that were phosphorylated in response to DNA damage 
(MATSUOKA et al. 2007). Accordingly, another recent screen in budding yeast uncovered 
a large number of novel Mec1fTel1-dependent phospho-substrates (SMOLKA et al. 2007); 
taken together these results suggest that the cellular functions under ATM/ATR and 
Mec1fTel1 control are numerous. In addition, while Mec1 has been shown to be the 
primary kinase responsible for phosphorylation of a number of Mec1fTel1 substrates 
including the checkpoint kinase Rad53 (SUN et al. 1996), a Tel1-specific screen has not 
yet been performed and it is unknown whether a subset or perhaps different set of 
substrates are phosphorylated in a Tel1-dependent manner. Supporting this, loss of TEL 1 
confers a defect in the MMS-dependent phosphorylation of the les4 subunit of the IN080 
chromatin remodeling complex, while loss of MEC1 does not (MORRISON et al. 2007). 
For Tel1 p's role in both the DDR and telomere metabolism, significant questions 
remain. While Tel1p is often thought to be functionally redundant with Mec1p in the DDR, 
recent studies have identified distinct Mec1-independent roles for Tel1 p in checkpoint 
signaling (MANTIERO et al. 2007), replication fork stability (DOKSANI et a/. 2009) and in the 
suppression of genome rearrangements (LEE et a/. 2008). None of the mechanisms 
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underlying these roles are well-understood. At telomeres, the straightforward model 
consisting of Tel1 p phosphorylation of Cdc13 leading to a conformational change that 
allows for recruitment of the Est1 subunit of telomerase has recently given way to more 
complex interactions potentially involving multiple kinases, rates of telomere end-
resection and other, possibly novel intermediates (GAO et al. 2010; MARTINA et al. 2012; 
Wu et al. 2013). Moreover, the mechanism(s) by which MRX and Tel1 are targeted to 
short telomeres is poorly understood but likely involves constituents of the shelterin 
complex (MARCAND et al. 1997; TEIXEIRA et al. 2004). 
Aim and significance of my dissertation research 
Despite recent characterizations of Mec1-independent roles for Tel1p in the DDR, 
these roles are apparently either non-essential, infrequently utilized or redundant with 
other pathways as the fact remains that the loss of TEL 1 alone does not confer sensitivity 
to DNA damaging agents. Thus, it remains a formal possibility that in addition to a strong 
genetic interaction with MEC1 in response to DNA damage (GREENWELL et al. 1995; 
MALLORY and PETES 2000; MORROW et al. 1995; RITCHIE et al. 1999), additional genetic 
backgrounds exists in which Tel1 function is required. In this dissertation, I describe first 
the results of data analysis I performed (along with work from my colleagues Pei Wang 
and Aravind Subramanian) of a large microarray dataset consisting of normal and A TM-
deficient cell lines treated with IR (Chapter 2). From this, we made the surprising 
observation that ATM-deficient cells, despite significant radiosensitivity, do not exhibit a 
significant defect in the transcriptional response to IR. Despite this, we culled from these 
data a set of radiation-responsive transcripts that as a signature for gene expression show 
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significant prognostic capability for outcome in breast cancer patients. Our microarray 
data further support the hypothesis that genetic interactions may suppress the effects of 
loss of A TMITEL 1. 
Following these additional observations, I generated a genome-wide genetic 
interaction library for tel1-11 interactions in the budding yeast and screened for interactions 
that cause IR- and MMS-sensitivity (Chapter 3). From these screens, I found that a 
diverse set of mutants interact with tel1-11 to cause synergistic DNA damage sensitivity. 
Due to the diversity of the identified tel1-11 xxx-11 interactions, I was surprised to find that 
the vast majority of these interactions also contributed to further shortening telomeres in 
tel1-11 cells. This work has revealed a surprisingly complex interplay between DNA 
metabolism, cellular dNTP levels and telomere lengths that underlie the DNA damage 
sensitivity of tel1-11 interactions. 
An overarching goal of this work and related work in the Paulovich laboratory is to 
uncover the so-called "missing-heritability" underlying genetic susceptibility to breast 
cancer. In short, despite prior success stories in identifying individual highly-penetrant 
breast cancer susceptibility loci such as BRCA 1 and BRCA2 (MIKI et a/. 1994; WOOSTER 
et a/. 1995), these cases represent a minority of breast cancer incidence. While twin and 
family studies reveal a strong genetic component for risk to so-called "common" forms of 
breast cancer (PETO and MACK 2000), large-scale GWAS efforts to map out this missing 
genetic component have been largely unsuccessful. While work is currently being 
undertaken to pursue exceedingly rare variants using next-generation sequencing-based 
approaches, an alternative hypothesis is that the genetic component underlying cancer 
susceptibility is due to gene-gene interactions, either due to the cumulative effect of 
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additive interactions of perhaps many mutant alleles or due to a strong synergistic effect 
between a small number of alleles (MANOLIO et al. 2009). Due to the combinatorial 
problem of accounting for two or more interacting variants genome-wide, even the large 
sample sizes associated with current GWAS and next-gen studies are ill-suited to this 
approach. Recent work from the Kruglyak lab has demonstrated that Saccharomyces 
cerevisiae is an ideal model system for mapping out such interactions, as large numbers 
of segregants can be rapidly genotyped and interacting QTLs can be efficiently mapped 
(BLOOM et al. 2013; EHRENREICH et al. 2012; EHRENREICH et al. 2010). Applying this 
methodology across a large number of quantitative traits, Bloom et al. observed both 
multi-gene additive effects and two-gene synergism for a variety of traits (BLOOM et al. 
2013). Alternatively, one may take a more directed approach and screen for genetic 
interactions in yeast with one or more fixed gene deletions. The Synthetic Genetic Array 
(SGA) approach, developed by the Boone laboratory (TONG and BOONE 2006; TONG et al. 
2001), leverages the non-essential yeast gene deletion collection to generate via a series 
of massively parallel mating and sporulation steps a set of double-knockout strains for 
identifying additive or synthetic interactions. This is the approach we have taken in the 
lab and the A TMITEL 1 interaction screen is part of a larger, ongoing project in which we 
have performed MMS-dependent interaction screens for the BRCA 1153BP1 ortholog 
RAD9 (MURAKAMI-SEKIMATA et al. 2010) and the XRCC3 ortholog RAD57 (HUANG et al. 
2013). While there is significant ongoing work in the lab to detect these gene-gene 
interaction effects via a targeted approach in large breast cancer datasets, we have 
shown that at least a subset of these DNA-damage-sensitive interactions can be 
recapitulated in human breast epithelial cells (Hu HM et al., in preparation). 
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CHAPTER 2: Transcriptional profiling of the ionizing radiation (lR) 
response in normal and A TM-deficient human Iymphoblasts. 
Tumor-derived gene expression signatures have recently shown utility for 
predicting clinical outcome in patients afflicted with a variety of cancer types. Studies have 
shown that activation of the DNA damage response pathway is a hallmark for early 
tumorigenesis, while loss of the DNA damage checkpoint is associated with disease 
progression. As such, we hypothesized that the transcriptional DNA damage response 
may serve as a prognostic signature for outcome in cancer patients. We comprehensively 
characterized the transcriptional DNA damage response in normal and A TM-deficient 
human lymphoblast cells, using v-irradiation to induce DNA lesions. We observed a 
robust transcriptional response to IR in Iymphoblasts; this response was surprisingly not 
dependent on A TM status. From these data, we developed a radiation-response 
signature, which we used to screen a panel of cancer datasets for the ability to 
characterize long-term survival of cancer patients. We demonstrate that genes induced 
or repressed by ionizing radiation predict clinical outcome in two independent breast 
cancer datasets and we compare the radiation signature to previously described gene 
expression-based predictors. While genes repressed in response to radiation likely 
represent the well-characterized proliferation signature predictive of outcome, genes 
induced by radiation likely represent other deregulated biological properties of tumors 
such as checkpoint or apoptotic responses. 
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For patients afflicted with breast cancer, there is considerable diversity in both the 
response to treatment and long term survival. Despite the availability of some individual 
markers for tumor classification (e.g. Her2, P53, estrogen and progesterone receptors), 
our ability to predict outcome or apply tailored therapy regimens remains limited. Efforts 
to develop new tumor classification assays, especially those based on panels of markers 
rather than individual markers, seek to provide better discrimination of clinically important 
subtypes of breast cancer. Gene expression arrays have shown considerable utility in this 
area, and early applications have identified highly stratified subtypes in multiple human 
cancers, extending the classification of tumors beyond that defined by traditional 
histological analysis and single biomarker measurements (KApP et al. 2006; LAPOINTE et 
al. 2004; PEROU et al. 2000). 
Complementarily, recent research has focused on the development of multi-gene 
expression signatures that correlate with patient outcome and that can be applied 
clinically to identify the most aggressive individual tumors. Such signatures have emerged 
for multiple tumor types (BARRIER et al. 2005; BEER et al. 2002). Specifically for breast 
cancer, no less than 8 different expression signatures have been proposed for predicting 
clinical outcome (reviewed in Sotiriou & Piccart, 2007) (SOTIRIOU and PICCART 2007). The 
first among these was developed by a group at the Netherlands Cancer Institute, and 
commonly referred to as the "Amsterdam signature". This 70-gene signature has shown 
significant prognostic capabilities (VAN 'T VEER et al. 2002; VAN DE VIJVER et al. 2002), 
culminating in the development of a custom-made microarray for high-throughput clinical 
screening and ongoing clinical trials (GLAS et al. 2006). Other signatures have followed, 
each introducing minor variations on the derivation of the signature or the exact type of 
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prediction. These include a model based on breast cancer recurrence (PAIK et al. 2004), 
a 76-gene signature developed for predicting distant metastasis (WANG et al. 2005), a 
signature based on expression subtypes known as the genomic grade index (SOTIRIOU et 
al. 2006), and a signature that is associated with loss of the PTEN suppressor and that 
has shown applicability to carcinomas from multiple tissues (SAAL et al. 2007). 
One underlying commonality among these breast cancer outcome signatures is 
that all were developed from gene expression datasets derived from tumor samples. In 
contrast, Chang et al. utilized a gene expression signature representing the "wound 
response" to accurately discriminate survival outcome in breast cancer patients (CHANG 
et al. 2005; CHANG et al. 2004). This signature, derived from human fibroblasts stimulated 
with serum, represents the first predictor developed completely independent of cancer 
patient samples or tumor cell lines. Instead, the signature was developed based on a 
hypothesis exploiting the similarities between cancer progression and wound healing. 
Genes upregulated in fibroblasts in response to serum stimulation were also shown to be 
upregulated in poor-prognosis tumors (CHANG et al. 2004). This study represents a novel 
methodology in cancer prediction: developing a prediction signature based on our 
understanding of the cellular mechanisms underlying tumorigenic progression. 
In 2005, two different research groups revealed that human precancerous (and 
early stage cancerous) lesions show constitutive activation of the DNA-damage response 
(DDR) pathway (BARTKOVA et al. 2005; GORGOULIS et al. 2005). It has been hypothesized 
that replication stress due to abnormal cell cycle progression activates the DNA damage 
checkpoint directly or through the sensing of DNA double-strand breaks (DSBs). Notably, 
this activation is associated with the induction of oncogene-induced senescence, which 
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is dependent on the OSB sensor kinase ATM (BARTKOVA et al. 2006; 01 Mlcco et at. 2006). 
As such, activation of the ONA damage checkpoint may act as a first line defense to halt 
tumor progression, and further mutations (P53, for example) may allow tumors to evade 
this mechanism. Thus, evaluating the activity of the OOR pathway and downstream 
effectors in human tumors may offer significant prognostic capabilities, similar to what 
has been shown for the wound response. 
In this study, we utilize microarrays to assay human lymphoblast cell lines with 
different A TM genotypes to identify radiation-responsive genes. We extend the current 
literature by reporting a number of transcripts not previously implicated as being radiation-
responsive and report that A TM-deficient cell lines do not exhibit a discernible defect in 
the transcriptional response to IR. Using the radiation-responsive genes as bait for Gene 
Set Enrichment Analysis (SUBRAMANIAN et a/. 2005), we identified a number of significant 
connections to human cancer, including correlation to clinical outcome in breast cancer. 
Following this observation, we demonstrate that our radiation-responsive signature 
serves as an effective predictor of survival outcome in two independent breast cancer 
datasets. We compare the radiation-response signature to previously developed outcome 
signatures, and show similar prognostic capability, despite varying degrees of gene/gene 
overlap. Like the wound-response signature, the radiation-response signature is an 
effective tumor outcome classifier derived from a biological hypothesis based on known 
tumor physiology (i.e. abnormal checkpoint function and chromosomal instability). 
Cell lines and growth conditions 
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Human lymphoblast (LBL) cell lines used in this study were obtained either from 
the Coriell Cell Repository (http://ccr.coriell.org/) or were kindly provided by Dr. Daniel 
Haber and Daphne Ball at the M.G.H. Charlestown Navy Yard. Fresh aliquots of cells 
were thawed and grown in RPMI 1640 + 15% FBS (Sigma, heat-inactivated) + 100 
units/ml penicillin + 100 ug/ml streptomycin in a humidified incubator at 37°C and 5% 
C02. Cells were fed by addition of fresh, pre-warmed medium 2-3 times per week as 
required to maintain culture density at 2-7 x 105 cells/mL until sufficient quantities of cells 
for the experiment were present (10-14 days). At this point, 2 x 107 cells were harvested 
by centrifugation and resuspended in 30 mL of fresh medium. Resuspended cells were 
then aliquotted into 3 x 10 mL identical samples in T25 Falcon tissue culture flasks and 
returned to the incubator where they were allowed to return to baseline following this 
manipulation. Specifically, the cultures were placed on the same shelf within the 
incubator, and the incubator door was not opened until the cells were irradiated 36-40 
hours later. 
LCL Irradiation 
Following the 36-40 hour recovery period described above, all cultures were 
removed en masse from the incubator, and transported on a cart to the Gamma-cell 40 
source. One aliquot of each culture was mock-irradiated whereas a second aliquot was 
exposed to 5.0 Gy using a 137CS gamma-Cell source operating at a dose rate of 96.1 
cGy/minute. Following exposure or mock exposure, all cultures were then returned to the 
incubator for 5 hours, after which they were harvested by centrifugation. The cell cycle 
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distribution (assessed by flow cytometry) of the Iymphoblasts was not significantly altered 
during the relatively short response period following exposure to IR (data not shown). 
RNA Isolation, hybridization, washing, scanning Affymetrix U133A and U133B 
chips 
Total RNA was extracted using a standard Trizol (Gibco BRL) extraction 
(CHOMCZYNSKI and SACCHI 1987; CHOMCZYNSKI and SACCHI 2006). RNA samples were 
quantified by absorbance at 260 nm, and purity was assessed by determining ratios of 
A260/A280. For first strand cDNA synthesis, 1 ml1 00 pmollml T7 -(T)24 primer (Genosys; 
GGCCAGTGAA TTGT AA T ACGACTCACT ATAGGGAGGCGG-(T)24) was hybrid ized to 
15 ug total RNA (65° C for 10 minutes, then transfer to ice) and subsequently incubated 
with 400U Superscript II reverse transcriptase (Gibco BRL) in 1X buffer for 1 hour at 42°C. 
Second strand cDNA synthesis was carried out using 40U DNA Polymerase I (Gibco 
BRL), 10 U DNA ligase (Gibco BRL), 2 U RNase H (Gibco BRL), and 0.23 mM dNTPs 
(Gibco BRL) in 1X buffer at 16°C for 2 hours. The resultant cDNA was cleaned-up by 
phenol extraction (PLG Phase-Lock Gel tubes, 5'-3') and ethanol precipitation. In vitro 
transcription (IVT) was carried out according to the manufacturer's recommendations 
(Ambion T7 MegaScript Kit) in the presence of Bio-11-CTP and Bio-16-UTP (Enzo). 
Resultant cRNAs were cleaned-up using Qiagen's RNeasy Mini Kit and fragmented in 1X 
RNA Fragmentation Buffer (5X stock: 200 mM Tris-Acetate, pH 8.1, 500 mM KOAc, 150 
mM MgOAc) for 35 minutes at 95°C. Fragmented cRNAs were hybridized to Affymetrix 
U133a and U133b arrays in MES Hybridization Buffer (100 mM MES, 1 M [Na+], 20 mM 
EDTA, 0.01 % Tween 20) at 45° C, 60 RPM, 16 hours. Control Oligo B2 (5'-Bio-
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GTCAAGATGCTACCGTTCA-3') was included. After hybridization, the probe arrays were 
washed (100 mM MES, 0.1 M [Na+], 0.01 % Tween 20), and the remaining biotin-labeled 
target was then stained with a Streptavidin R-Phycoerythrin (Molecular Probes). The 
signal was then amplified with a Biotinylated anti-Streptavidin Ab (goat; Vector Lab), 
followed by a second staining with the streptavidin-conjugated fluorescent stain prior to 
scanning. 1X Stain Buffer contained 100 mM MES, 1 M [Na+], 0.05% Tween 20,0.005% 
Antifoam. Arrays were scanned using a Hewlett Packard (HP) scanner using MAS5 
software (www.affymetrix.com). and the final dataset was normalized using RMA 
(quantile norm, default settings) (IRIZARRY et al. 2003). 
Microarray Data Analysis 
To search for genes differentially expressed between the irradiated group and 
unirradiated group, the Signal to Noise Ratio (SNR) was calculated for each of the 44760 
probe sets as follows: 
where IJO,i and OO,i are the mean and variance of the ith probe set of the irradiated 
experimental group and 1J1,i and 01,i are the mean and variance of the unirradiated 
grouping. (i ranges from 0 to 44759). The dateset was permuted 5000 times to generate 
a null distribution from which the q-value statistic was applied to correct for multiple 
hypothesis testing (STOREY and TIBSHIRANI 2003; TUSHER et a/. 2001). 
Pathway analysis using GSEA (SUBRAMANIAN et a/. 2005) was done in two different 
ways. First, a priori defined Gene Sets were tested against the radiation response for 
discrimination between the irradiated and unirradiated states. Gene Sets were compiled 
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from the Gene Ontology consortium (ASHBURNER et al. 2000). Ontologies were separated 
at top level categories (Biological Process, Cellular Component and Molecular Function) 
and Gene Sets were created by iteration over all subcategories and placing all genes 
common to a subcategory in a Gene Set representing that subcategory. Gene Sets 
containing <25 or >500 genes were excluded from the analysis. Other parameters used 
as input for the GSEA program were as follows: the algorithm was Signal2Noise, 
normalization method was meandiv, permutations were done by phenotype, the scoring 
scheme was weighted, and 1000 permutations were used for each analysis. 
Curation of Expression Datasets from the Literature 
The NKI expression data set and patient clinical information (VAN DE VIJVER et al. 
2002) were downloaded from the Stanford University public repository (http://microarray-
pubs.stanford.edu/). There are 244 arrays in total with 24136 clones on each array. Global 
normalization was performed (center mean was set to zero and MAD (median absolute 
deviation) was set to 1). A second expression data set described in Loi et. al. (Lol et al. 
2007) was downloaded from the Gene Expression Omnibus database 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE6532). There are 277 arrays 
(from patients who received adjuvant tamoxifen treatment) with 44928 clones on each 
array. The dataset representing irradiated mammary tumor epithelial cells and lymphoid 
tumor cells was extracted from a larger dataset published by Amundson et al. (AMUNDSON 
et al. 2008), and the raw measurements were quantile normalized (R package "DNAMR"). 
Analysis of Expression Signatures in Curated Expression Datasets 
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Statistical analysis was conducted using the open source program R 
(http://lib.stat.cmu.edu/R/CRAN/). For hierarchical clustering, each gene was 
standardized to mean=O and MAD=1. Euclidean distance was used with complete linkage 
in the R function hclust to derive hierarchical clustering. For survival analysis, the R 
package sUlVival was used to plot Kaplan-Meier survival curves. Log-rank tests were 
performed for comparing Kaplan-Meier curves of two different groups. The RI (or RR) 
signature of a sample was defined as the projection of measurements of the RI (or RR) 
genes on the first principle component direction of the RI (or RR) gene set across all the 
samples. These RI (or RR) signatures were then used in various Cox proportional hazard 
models fitted with the R function coxph. The Fisher exact test was performed using the R 
function fisher.test. To identify genes serving as the key drivers of the clustering, we used 
a two-sided t-statistic. We controlled for multiple hypothesis testing by deriving q-values 
(R packages testp, and qvalue). 
In the classification analysis, patients were first separated into two groups: the poor 
clinical outcome group (deceased within 10 years of follow-up) and the good clinical 
outcome group. Then, for each gene signature, leave-one-out cross validation was 
performed as follows: (1) For a selected test sample, we treated the rest of the data as 
the training set.; (2) We calculated the mean expression level for the training samples in 
the good- and bad-survival groups, and computed the distance between the expression 
level of the test sample and the centroids of the good- and poor-survival groups: 
P (* -)2 
d(X*) = L Xi -Xik 2 -21ogJZ'k 
i=! (Si + so) 
where x' = {X;}i is the expression of the test sample; p is the total number of genes in 
this gene list; {X;k}i is the centroid of class k( = 1 or 0); Si is the standard deviation of Xi ; 
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So is set to be 0.01 here; T[k is the proportion of samples in class k. (3) We then classified 
the test sample into the class with the smallest distance. (4) Lastly, we repeated the 
process with a new test sample until we had iterated over all samples. 
Based on the classification results of the 8 gene signatures, we further divided the 
patients into 5 groups based on both the true outcomes and the classification by the 
expression signatures. We then compared the distribution of other known clinical 
variables in group 1 (good survival and classified as "good") vs. 3 (bad survival but 
classified as "good"), and group 2 (poor survival but classified as "good") vs. group 4 (poor 
survival and classified as "poor"). 
Normal human lymphoblast cells exhibit a robust transcriptional response to 
ionizing radiation 
To comprehensively characterize the human transcriptional response to y-
irradiation in human cells with a functional A TM gene or lacking one or two copies of A TM, 
we profiled 12 different A TM+/+ lymphoblast cell lines (LBL), 10 different A TM+/- lines 
and 10 different ATM-/- cell lines at 5 hours following exposure to 5 Gy irradiation. Control 
samples were mock-irradiated. From this transcript array dataset, we first asked whether 
a robust transcriptional response was observable in normal human Iymphoblasts (i.e. 
ATM+/+). By discriminant analysis, we determined 160 genes were induced by radiation 
(211 probe sets) and 59 genes repressed by IR (70 probe sets) at FOR::;; 0.05 (Table 1 
and 2). This large study identified known radiation-responsive transcripts (e.g. GADD45A, 
XPC, PPM 1 0, FAS, etc.) as well as many genes not previously implicated in the radiation 
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response (e.g. ZNF79, C11orf24, CSNK1G1, KCNN3, etc.). The radiation-induced (RI) 
genes function in a number of different cellular pathways including apoptosis signaling 
and cell cycle arrest, as determined by Gene Ontology (GO) (ASHBURNER et al. 2000) 
category enrichment; radiation-repressed (RR) genes function predominantly in cell 
division (Table 3 and 4). 
ATM-deficient cells mount a normal transcriptional response to IR 
As cells lacking ATM are highly sensitive to IR, we next hypothesized that ATM-/-
cells from AT patients would manifest a transcriptional defect compared to the wild-type 
cell lines. However, discriminant analysis between the 12 irradiated A TM+/+ cell lines and 
the 10 ATM-/- cell lines did not reveal any significant differences at an FOR of 1 %, 
showing that ATM-/-Iymphoblast cell lines mount a normal transcriptional response to IR. 
Accordingly, ATM+/- cell lines also did not exhibit any transcriptional differences after IR 
when compared to wild-type cells at an FOR of 1 %. Additionally, comparisons between 
the A TM+/+, A TM+/- and A TM-/- in the mock-irradiated samples did not reveal any 
significant differences in basal transcription levels. From these data, we conclude that 
despite a radiosensitive phenotype, A TM-/- lymphoblast cells exhibit a transcriptional 
response to 5 Gy IR at 5 hours that is indistinguishable from ATM+/+ cells. 
ATM-deficient Iymphoblasts exhibit a defect in DDR signaling that is exacerbated 
by treatment with the Pl3-like kinase inhibitor caffeine 
The fact that A TM-/- lymphoblast cells did not exhibit a transcriptional defect in response 
to 5 Gy of IR was surprising given the fact that ATM-/- cells have a well-characterized 
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defect in phosphorylating the DNA damage responsive transcription factor TP53 (BANIN 
et aJ. 1998; CAN MAN et a/. 1998) in response to similar doses. Thus we asked whether in 
the cell lines utilized in this study, we observe a defect in TP53 phosphorylation at the 
dose and time utilized in the microarray experiments. As seen in Figure 1, the treatment 
of normal Iymphoblasts with ionizing radiation results in a significant increase in TP53 
phosphorylation in a dose- and time-dependent manner (Figure 1 a&b). However, in the 
A TM-/- line, we observe a both a delay in radiation-induced TP53 phosphorylation as well 
as a significant decrease in overall TP53 phosphorylation levels relative to the ATM+/+ 
Iymphoblasts. Of note, at the 5 hour timepoint, we observe a significant amount of residual 
phosphorylation in A TM-/- cells that may be sufficient to activate TP53 transcription factor 
activity. This residual activity is likely due to substrate overlap with other DDR signaling 
kinases such as ATR and DNA-PK (YANG et a/. 2003). As such, we hypothesized that 
treating A TM-/- cells with the Pl3-like kinase inhibitor caffeine would completely abolish 
this residual activity. As expected (Figure 1 c), treatment of irradiated ATM-/- cells with 
increasing doses of caffeine completely abolished TP53 phosphorylation. From these 
data we conclude that redundancy in the DDR kinase-substrate network suppresses the 
signaling defect in A TM-/- cells and may contribute to the lack of transcriptional 
differences between irradiated A TM+/+ and A TM-/- Iymphoblasts. 
Radiation Signature in Human Cancer Datasets 
Due to the vital role of the DNA damage response pathway as a mechanism for 
resistance to tumorigenesis (BARTKOVA et aJ. 2006), as well as the importance of radiation 
therapy in treating human cancer, we next explored the prognostic capabilities of 
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radiation-responsive genes in human cancer datasets. We initially used the GSEA 
algorithm (SUBRAMANIAN et a/. 2005) to screen the list of 160 radiation-induced (RI) genes 
and 59 radiation-repressed (RR) genes for correlation with a series of clinical traits in a 
panel of cancer microarray datasets curated from the literature. These traits included: 
clinical outcome in multiple cancer types (BEER et al. 2002; BHATTACHARJEE et a/. 2001; 
MONTI et a/. 2005; NUTT et a/. 2003; POMEROY et a/. 2002; SINGH et al. 2002; VAN DE VIJVER 
et a/. 2002), estrogen receptor status in breast cancers (VAN DE VIJVER et a/. 2002; WEST 
et al. 2001), BRCA 1 status in breast cancers (VAN 'T VEER et al. 2002), and P53 status in 
multiple cancer cell lines (RAMASWAMY et al. 2001). The results of this screen are 
presented in Table 5. The breast cancer datasets yielded particularly interesting results, 
including correlation of a radiation-derived gene set with clinical outcomes as well as both 
estrogen receptor and BRCA 112 mutant status. 
Following these observations from the initial screen, we further assessed the 
prediction capabilities of the radiation signature in breast cancer using a more thorough 
analysis. We focused on the clinical outcome dataset consisting of 244 breast cancer 
patients from the Netherland Cancer Institute (NKI) (VAN DE VIJVER et a/. 2002). After 
applying a stringent filter to minimize false positives in the radiation signature (q-value :5 
0.02, SNR ~ 1.2), we identified 50 RI genes and 68 RR genes. We cross-mapped the 
radiation-induced and radiation-repressed signatures to the NKI dataset (15 RI genes + 
31 RR genes overlapped) and clustered tumor samples in the space of the genes 
repressed by radiation (the RR gene set) or the space of genes induced by radiation (the 
RI gene set). As shown in Figure 2A, by applying hierarchical clustering, the RR gene set 
naturally separated the tumor samples into two distinct clusters based solely on the 
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expression of RR genes. We next performed Kaplan-Meier survival analysis on the two 
clusters (Panel 28), and observed that primary tumors from the left cluster (Fig. 2A) were 
significantly more likely to progress to death than tumors from the right cluster (p = 2.13 
x10-7, log rank test). To determine the probability that this separation could be due to 
random chance, we repeatedly sampled a gene set of the same size (31 genes) from the 
original expression data set and again clustered the data and performed the log rank test. 
In 3 out of the 500 iterations, the log rank test p values were smaller than our calculated 
p-value; hence, the possibility of observing this association by chance was 0.006. We 
repeated the analysis using the RI signature, which also separated the tumor samples 
into good- and poor-outcome clusters (Figure 2 C&D). The log rank test for the difference 
in outcome between the clusters yielded a p-value of 0.0006, which corresponds to an 
error rate of 0.034 based on random sampling (17 out of 500 iterations have the same or 
smaller p-value). 
We also tested for an association between tumor clusters (separated by radiation 
genes, Figure 2 A & C) and tumor grade and ER status, which are represented visually 
above the heatmaps in Figure 2 A & C. Tumor Grade was strongly correlated to the RR 
and RI gene sets, with the two clusters accurately separating poorly- and well-
differentiated tumors (the p-value for RR 2.58 X10-12 , p-value for RI was 0.00092). 
Estrogen receptor status was also correlated with the RR set (p-value = 2.05 x10-8) but 
not significantly correlated with the RI signature (p-value = 0.074). We conclude that the 
RR and RI signatures show a strong correlation with tumor grade, and the RR signature 
shows correlation with estrogen receptor status. 
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To extend and validate these results, we tested the prognostic power of the 
radiation-repressed and induced gene signatures in an additional independent breast 
cancer microarray dataset providing survival annotation (Lol et al. 2007). For the recently 
published Loi et al. dataset (Lol et al. 2007), we again cross-mapped the RI and RR genes 
to this dataset (41 RI + 51 RR genes overlapped) and performed clustering analysis in 
the space of either the RR or RI genes (Figure 3A & C). As before, the RR signature 
yielded two distinct clusters (Figure 3A), with the left cluster showing significantly higher 
mortality (Figure 38, p-value=0.009). The left cluster was also significantly associated 
with grade 3 tumors (44/47 patients, p=1.0e-09). As was observed in the NKI dataset, the 
RI signature separated the samples into two distinct clusters (Figure 3C), which showed 
significant differences in clinical outcome (Figure 3~). The log rank test for the difference 
in outcome between the clusters yielded a p-value of 0.023, which corresponds to a 
random chance of 0.05 based on random sampling (27 out of 500 iterations have the 
same or smaller p-value). The clustering by RI genes was again correlated with tumor 
grade, with the left cluster enriched for poor-outcome tumors (Figure 3C, p-value = 
0.0057). We conclude that the RR and RI signatures are prognostic for breast cancer, 
which has been demonstrated in two independent patient populations. 
TP53 is a major factor controlling the transcriptional response to ionizing radiation 
(JEN and CHEUNG 2005), and TP53 status is associated with poor outcome in breast 
cancer (THOR et al. 1992). Hence, we hypothesized that aberrant regulation of the RI 
genes (predictive of poor outcome) could be a result of altered TP53 activity in the poor 
outcome tumors. To test this hypothesis, we determined whether genes that were the key 
drivers of the outcome clustering were known transcriptional targets of TP53. Genes that 
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exhibit the largest expression difference between the two clusters are the key drivers of 
the clustering of breast tumors (Figures 2 & 3). We ranked the 41 RI genes by their 
differential expression between the good vs. poor outcome clusters in the Loi et al. dataset 
and asked if these genes are known to be regulated by P53 (Table 6). Many of the key 
drivers for this clustering are not known P53-regulated genes (Table 6), suggesting that 
either these are novel p53 targets or that the RI genes are not entirely p53-regulated. 
Moreover, when we removed the non-P53 regulated genes from the RI signature and 
repeated the clustering, there was no significant discrimination between good- and poor-
outcome tumors (data not shown), demonstrating that the genes not known to be p53-
responsive are important for discriminating outcome. We conclude from these results that 
the predictive power of the RI signature is not entirely dependent on known P53-
responsive genes. Moreover, we compared our RR and RI signatures with a previously 
published 32 gene P53 signature derived from transcriptional differences between P53 
mutant and wildtype breast tumors (MILLER et al. 2005). Neither the RR nor RI signatures 
showed any overlap with the 32 genes in this P53-derived signature. We conclude that 
the tumor-derived P53 signature is not similar to the radiation response signature derived 
from non-tumor cells. This is perhaps not surprising as breast tumors commonly have a 
defective DNA damage response. 
The radiation response signature was derived from lymphoblast cell lines. Because 
the radiation response may vary amongst cell types of origin, we sought to observe 
whether a signature derived from irradiated breast epithelial cell lines would prove to be 
a stronger predictor. To do this, we analyzed a subset of samples from a recently 
published study looking at gene expression across a panel of tumor cell lines derived 
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from a variety of tissues (AMUNDSON et 81. 2008). From this dataset, we analyzed 
microarray data from the 5 breast cancer cell lines untreated versus 8 Gy IR. Analysis of 
this dataset yielded 66 induced and 10 repressed genes at a FOR ~ 0.02 (Table 7). None 
of these genes overlapped with our lymphoblast-derived radiation gene sets. (Of note, 
this breast tumor line dataset represents a small number of tumor lines on a custom array 
platform of < 7000 genes, so its power to derive a predictor may be poor.) Unlike the 
radiation signature derived from the lymphoblast study, the gene set derived from the 
mammary epithelial tumor cell lines was not able to significantly distinguish good- from 
poor-outcome tumor samples (data not shown). Because tumors harbor known defects 
in the DNA damage response, it is perhaps not surprising that radiation signatures derived 
from tumor cell lines do not predict outcome in breast cancers. It is still conceivable that 
a radiation signature derived from primary mammary epithelial cells could yield a stronger 
predictor than that derived from Iymphoblasts, but no such dataset is currently available 
to test this hypothesis. 
Comparison of Outcome Signatures 
Next, we used a Cox proportional hazard model to determine the relationship 
between the radiation signatures and known clinical parameters (and the wound response 
signature) in the NKI dataset. First, we generated a univariate Cox model to assess the 
predictive capabilities of the radiation and wound response signatures in the NKI dataset. 
In a univariate analysis (Table 8, left panel), the RI signature, RR signature, wound 
response, and five clinical variables (age, lymph node status, tumor grade, vascular 
invasion, and ER status) are significant risk factors for poor clinical outcome (p 
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value<0.05). Additionally, the combined RI and RR gene set yielded a significant hazard 
ratio, with a p-value of 3e-9. Next we performed multivariate analysis to determine the 
performance of the RR and RI signatures combined with clinical parameters and the 
wound response signature (Table 8). This was performed both with the RR and RI 
signatures separately (Model 1), and combined (Model 2). In the first model, both the RR 
signature and the age of the patient yielded significant hazard ratios, but notably the RI 
signature did not. However, using the combined RR and RI signature yielded a significant 
p-value in the multivariate model (p=0.021) that was marginally lower than the RR 
signature alone (0.030) (Table 8 model 2). As the combined radiation signature yielded a 
significant hazard ratio in the multivariate model, we conclude that this signature offers 
additional information with other clinical variables and the wound response signature. 
The Cox analysis was then repeated for the Loi ef al. dataset (Table 9). Once 
again, both the RR and RI sets (separately or combined) are strong risk factors in the 
univariate analysis. In the multivariate analysis with other clinical parameters (Table 9, 
Model 1), ER status was the predominant risk factor in the model using RR and RI as 
separate sets (p-value = 0.015). However, as with the NKI dataset, when the RR and RI 
are combined into a single set (Table 9, Model 2), the radiation signature is highly 
significant, with a p-value of 0.009 (ER status has a p-value of 0.019 in this model). This 
strongly suggests that the combined radiation gene signature offers significant potential 
in predicting outcome, and provides additional information about the tumor in combination 
with known clinical factors and the wound response signature. 
We next compared the RR and RI signatures to previously published signatures in 
terms of gene overlap and prognostic power. Other signatures used in this comparison 
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were the Amsterdam 70 gene (VAN DE VIJVER et al. 2002), the wound response (CHANG et 
al. 2004), the 76-gene metastasis signature (WANG et al. 2005), the recurrence score 
(PAIK et al. 2004), the Genomic Grade Index (GGI) (SOTIRIOU et al. 2006), and the PTEN 
signature (SAAL et al. 2007). We first computed the overlap in gene membership between 
the RR and RI signatures and the other outcome signatures. We observed that the GGI 
and PTEN signatures showed some overlap with the RR signature (34 and 11 genes, 
respectively), while the other signatures yielded minimal overlap (Table 10). The overlap 
with the GGI signature includes 14 of the top RR genes (ranked by p-value), which are 
comprised mostly of cell cycle and mitosis-related factors. The lesser overlap with some 
of the other signatures is perhaps due to design, as the authors of the Wound Response 
and PTEN signatures specifically excluded cell cycle-related genes from the final list. 
(Indeed, matching the RR signature to the 193 genes removed from the Wound Response 
signature yielded an overlap of 28 genes.) 
Next, we compared the prognostic capability of the radiation-repressed signature 
to previously published breast outcome signatures using the NKI dataset (VAN DE VIJVER 
et al. 2002). This comparison was done using the leave-one-out cross validation 
procedure, which consisted of calculating the mean expression of each signature with 
respect to the good and poor outcome groups, and comparing the distances of the left-
out sample with the centroid of each group (see Methods). The results for each signature 
are reported in Table 11. Despite differences in the size of the gene sets, the signatures 
showed similar error rates and sensitivity for classifying patients for outcome. 
To examine if a subset of tumors was commonly misclassified by all of the gene 
signatures, we plotted a heatmap of classification status for each sample as determined 
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by each of the 8 prediction signatures (Figure 4). Each signature was used to predict the 
classification of patients into groups representing survival past 10 years (the good clinical 
outcome group), and those which died prior to 1 O-years (the poor clinical outcome group). 
Most patients are generally grouped into the same clusters by each signature, 
demonstrating good concordance amongst the signatures (Figure 4). Interestingly, there 
exists a subset of tumors that are misclassified by all or most of the gene signatures. For 
example, in the poor-outcome group, there is a subgroup of 10-20 patients that are 
commonly misclassified as "good" by most signatures. Conversely, in the good-outcome 
group, a similarly sized subset of samples has been misclassified as "poor" by most 
signatures. We next examined whether misclassification of tumors was associated with 
the other known clinical parameters for which annotation was available (age, diameter, 
lymph node metastasis, tumor grade, vascular invasion, ER status, mastectomy, and 
chemotherapy; see Tables 12 and 13). For poor-outcome patients that were misclassified 
as "good outcome" by the majority of expression signatures, both ER- status (p=1.0E-05) 
and high Tumor Grade (p=0.03) were enriched. In contrast, no clinical variables were 
significantly enriched in tumors associated with good outcome but misclassified as poor 
outcome. We conclude that all gene expression signatures perform very similarly in tumor 
classification, and that there are subsets of both poor- and good-outcome samples that 
are commonly misclassified by all of the signatures. 
Questions that arise from this study are why a transcriptional Signature of the 
cellular radiation response shows prognostic capabilities in breast cancer, and how is the 
radiation-derived predictor different from other known predictors in breast cancer? There 
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are interesting parallels between tumorigenesis and the radiation response (Figure 5). 
Key drivers of tumorigenesis are the activation of oncogenes (stimulating deregulated 
proliferation) and the inactivation of tumor suppressor genes (leading to defects in 
checkpoint function and apoptotic responses) (Figure 5A). Similarly, in response to 
radiation, there is a rapid transcriptional response consisting of both up- and down-
regulation of genes, wherein down-regulated genes are involved in driving progression 
through the cell cycle (proliferation) and up-regulated genes are involved in checkpoint 
inhibition of cell cycle progression and apoptosis (Figure 58). 
The majority of outcome signatures for breast cancer essentially detect the same 
property: the high potential for proliferation in poor outcome tumors (SOTIRIOU and 
PICCART 2007). Hence, it is not surprising that the set of genes repressed by radiation in 
our study is able to predict breast cancer outcome, since this gene set is enriched in 
genes involved in cell cycle progression/proliferation (Table 4). We suggest that the 
reason most breast outcomes signatures to date focus on proliferation is that they were 
trained on gene expression array datasets from human tumors, in which the strongest 
transcriptional program driving this clustering is one associated with a singular biological 
property: proliferation. However, these results do not imply that additional biological 
properties of breast cancers, whose transcriptional correlate is not as strong as that of 
the proliferation signature (and hence does not drive the hierarchical clustering of tumors), 
may also carry significant prognostic information. 
Indeed, our finding that the set of genes induced by radiation (RI) are enriched in 
checkpointiapoptotic functions and are distinct from the proliferation cluster indicates that 
the RI signature may contain novel predictive information, less related to high proliferation 
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and likely representing additional tumor properties such as genomic instability. In addition 
to genes involved in apoptosis and cell cycle arrest, a number of functional pathways not 
previously implicated in the radiation response were among the top radiation-induced 
pathways. Foremost among these were the categories corresponding to 
glycosaminoglycan, aminoglycan, and proteoglycan metabolism (Table 3). Perhaps 
relatedly, proteoglycans such as heparan sulfate have been shown to be linked to tumor 
progression (SANDERSON ef al. 2004). 
Also consistent with our observation that the RI gene set carries prognostic 
information, others have shown that human precancerous (and early stage cancerous) 
lesions consistently show constitutive activation of the DNA-damage response (DDR) 
pathway due to the initial replication fork breakdown to double-strand breaks (DSBs) in 
proliferating cells, and this activation disappears as tumors progress (Figure 5A) 
(BARTKOVA ef al. 2005; GORGOULIS ef al. 2005), suggesting that the DNA damage 
checkpoint acts as an anti-proliferative barrier for tumorigenesis (BARTKOVA ef al. 2006; 
01 Mlcco et al. 2006). Hence one can imagine that a lack of this checkpoint would be 
associated with tumor progression and poor clinical outcome. Additionally, activity of the 
p53 pathway (via changes in p53 or its regulator MDM2) has been associated with 
survival in breast cancer (BOERSMA et al. 2006; ISOLA et al. 1992; PHAROAH et al. 1999; 
THOR et al. 1992; THORLACIUS et al. 1995), although poor standardization of the p53 
immunohistochemistry-based assay coupled to the complex autoregUlatory feedback of 
this pathway have confounded the results (MCSHANE et al. 2000). 
Because P53 is one of the main transcriptional activators in the normal radiation 
response, and poor-outcome tumors are commonly P53 negative, it can be hypothesized 
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that the RI signature's predictive power is at least partially derived from P53 status. As 
predicted, P53 regulated genes make up a significant component of the RI signature. 
However, as we showed in Table 6, many of the genes that drive the clustering into a 
good- and poor-outcome group are not known to be regulated by P53. This suggests that 
either many of these genes are actually P53 targets that have not yet been discovered, 
or that the RI signature's predictive capabilities are not entirely P53- dependent, 
representing a novel connection between the radiation response and tumor outcome. 
Despite an overwhelming body of evidence indicating the potential clinical prognostic 
utility of the DDR pathway in human breast cancer, the lack of a clinically tractable robust 
assay to assess the activity of this pathway has prevented its translation into clinical care 
of breast cancer patients (HARRIS et al. 2007). Because the DDR pathway contains p53-
dependent and p53-independent responses, p53 status alone does not completely 
assess the activity or functionality of the signal transduction cascade (HARPER and 
ELLEDGE 2007). Hence it is likely that the (thus far) nearly exclusive focus of clinical testing 
on p53 has failed to fully prosecute this complex cellular pathway as a clinical marker. 
The RI signature, which encompasses multiple facets of the DDR pathway, serves as an 
initial foray into a more robust DDR signature for prognostication, and further 
characterization of a number of the key drivers for this clustering may reveal the extent to 
which the DDR pathway is represented in the RI signature. 
Of note, our radiation-responsive transcriptional study was performed in cell lines 
of Iymphoblastoid origin, yet the signature serves as an excellent predictor of survival 
outcome in mammary epithelial tumors. This is not the first predictive signature to be 
derived from an entirely different cell type. The wound response signature (CHANG et al. 
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2004) is another efficient predictor of survival outcome in breast cancer, but was in fact 
derived from serum-stimulated fibroblast cells. The transcriptional radiation response of 
lymphoid cells has previously been shown to be applicable to other tissues as well, in 
particular for predicting radiotoxicity of normal tissues in prostate cancer patients treated 
with radiation therapy (SVENSSON et al. 2006). It is unknown how the radiation response 
differs among different normal cell types. 
Like the wound response signature, the radiation signature offers additional 
support for the development of gene expression signatures based on known pathways 
whose mutations contribute to tumorigenesis. As tumor progression may proceed through 
a series of mutations affecting multiple pathways, one can imagine the utility of a panel 
of gene expression signatures for tumor diagnosis, each based on the functionality of a 
specific anti-tumor barrier. Such a tactic has root in the idea of the "Vogelgram," in which 
tumorigenesis can be understood as a multi-step genetic progression (KINZLER and 
VOGELSTEIN 1996). An ordered panel of pathway- specific gene expression changes may 
offer a complete picture of the genomic landscape for specific tumors, and could 
determine where each tumor sits in such a progression model. Such data would be 
important for both prognosis and deciding on a plan of treatment (BILD et al. 2006). 
In a 2006 analysis, Fan et al. showed that despite minimal overlap between cancer 
outcome signatures, each yielded similar prognostic capabilities (FAN et al. 2006). Our 
results with the radiation-response signature agree with this assessment; for example, 
we show the signature has similar performance in tumor classification, and in general a 
low degree of overlap with other outcome signatures. The fact that all expression 
signatures identified a number of poor-outcome tumors that were not predicted by other 
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clinical parameters is particularly encouraging, but outlines a significant need for 
additional clinical datasets for verification. This would also allow testing of whether the 
misclassification of certain samples is reproducible, and help uncover a group of tumors 
that aren't easily classifiable by any available means. Such an investigation may help 
further refinement of molecular signatures to encapsulate these tumors, and a thorough 
study may help identify new discriminant genes, or even extrinsic factors related to early 
death that aren't direct properties of the tumor (overall patient health, etc.). 
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rank radiation-repressed gene symbol Score FOR Feature P QValue Fold Change 
1 qclinB1 CCNB1 3.02 0.002 4.00E-05 0.026 3.8 
2 aurora kinase A AURKA 2.64 0.002 4.00E-05 0.026 1.8 
3 cell division cycle 20 homolog (S. CDC20 2.45 0.002 400E-05 0.026 4.6 
4 kinesin family member 20A KIF20A 2.19 0.002 4.00E-05 0.026 2.2 
5 [polo-like kinase 1 (Drosophila) PLK1 2.14 0.002 4.00E-05 0.026 2.1 
6 ubiquitin-conjugating enzyme E2C UBE2C 2.09 0.002 4.00E-05 0.026 1.8 
7 hypothetical protein DKFZpJ62E1 DKF8J762E1 1.90 0.002 4.00E-05 0.026 1.4 
8 cyclin B2 CCNB2 1.71 0.002 4.00E-05 0.026 1.9 
9 transforming, acidic coiled-coil co TACC3 1.62 0.002 400E-05 0.026 1.6 
10 TPX2, microtubule-associated, ho TPX2 1.61 0.002 4.00E-05 0.026 1.9 
11 centromere protein A CENPA 1.55 0.002 4.00E-05 0.026 2.4 
12 centromere protein F, 350/400ka CENPF 1.50 0.002 400E-05 0.026 1.9 
13 aurora kinase A AURKA 1.42 0.002 4.00E-05 0.026 1.9 
14 discs, large homolog 7 (Drosophil DLG7 1.42 0.002 4.00E-05 0.026 2.5 
15 splicing factor, arginine/serine-rier SFRS7 1.39 0.002 4.00E-05 0.026 1.3 
16 cell division cycle associated 8 CDCA8 1.36 0.002 4.00E-05 0.026 1.6 
17 cell division cycle associated 3 CDCA3 1.35 0.002 4.00E-05 0.026 1.6 
18 trophinin associated protein (tastir TROAP 1.33 0.002 4.00E-05 0.026 1.3 
19 G-2 and S-phase expressed 1 GTSE1 1.33 0.002 4.00E-05 0.026 1.6 
20 G-2 and S-phase expressed 1 GTSE1 1.31 0.002 4.00E-05 0.026 1.4 
21 karyopherin alpha 2 (RAG cohort KPNA2 1.30 0.002 4.00E-05 0.026 2.1 
22 a~ (abnormal spindle) homolog, ASPM 1.26 0.002 4.00E-05 0.026 1.4 
23 centromere protein A CENPA 1.26 0.002 400E-05 0.026 1.4 
24 cyclin F CCNF 1.21 0.002 4.00E-OS 0.026 1.4 
25 chromosome 13 oQ.en reading_ fra C13orf34 1.18 0.002 4.00E-OS 0.026 1.S 
26 CDC28 protein kinase regulatory CKS2 1.16 0.003 8.00E-OS 0.028 2.1 
27 dyskeratosis congenita 1, dyskerir DKC1 1.13 0.003 8.00E-OS 0.028 1.2 
28 hyaluronan-mediated motilityrece HMMR 1.11 O.OOS 1.20E-04 0.037 1.6 
29 DEP domain containing 1 DEPDC1 109 0.002 4.00E-OS 0.026 1.S 
30 cyclin A2 CCNA2 1.08 0.005 1.20E-04 0.037 1.8 
31 chromosome 15 ()Q.en reading_ fra C1Sorf23 1.08 0.002 4.00E-OS 0.026 1.5 
32 [proline/serine-rich coiled-coil 1 PSRC1 1.0S 0.002 4.00E-OS 0.026 1.3 
33 antigen identified by monoclonal a MKI67 1.0S 0.006 1.60E-04 0.043 1.5 
34 Ran GTPase activating protein 1 RANGAP1 1.0S O.OOS 1.20E-04 0.037 1.3 
35 unc-84 homolog B (C. elegans) UNC84B 1.04 0.006 1.60E-04 0.043 1.4 
36 antigen identified by monoclonal a MKI67 1.04 0.005 1.20E-04 0.037 1.4 
37 solute carrier family_ 38, member 1 SLC38A1 1.02 0.003 8.00E-OS 0.028 1.4 
38 G-2 and S-phase expressed 1 GTSE1 1.01 O.OOS 1.20E-04 0.037 1.2 
39 RAD21 homolog (S. pombe) RAD21 1.00 0.007 2.00E-04 0.049 1.5 
40 qclin-deQ.endent kinase inhibitor CDKN3 0.99 0.002 4.00E-OS 0.026 1.6 
41 SEC14-like 1 (S. cerevisiae) SEC14L 1 0.99 0.003 8.00E-OS 0.028 1.4 
42 hyaluronan-mediated motility rece HMMR 0.97 O.OOS 1.20E-04 0.037 1.8 
43 baculoviral lAP repeat-containing BIRCS 0.96 0.006 1.60E-04 0.043 1.5 
44 tumor necrosis factor (TNF superl TNF 0.96 0.007 2.00E-04 0.049 1.4 
45 centromere protein F, 350/400ka CENPF 0.95 0.003 8.00E-OS 0.028 1.2 
46 BUB1 budding uninhibited byben BUB1B 0.9S O.OOS 1.20E-04 0.037 1.6 
47 DEP domain containing 1 DEPDC1 0.9S 0.002 4.00E-05 0.026 1.7 
48 transmembrane protein 113 TMEM113 0.9S 0.013 4.00E-04 0.082 1.7 
49 non-SMC condensin I complex, St NCAPD2 0.94 0.007 2.00E-04 0.049 1.3 
50 hypothetical protein HSPC 111 HSPC111 0.94 0.002 400E-OS 0.026 1.3 
51 NIMA (never in mitosis gene a)-re NEK2 0.93 0.006 1.60E-04 0.043 1.3 
52 epithelial cell transforming seQuen ECT2 0.93 0.019 600E-04 0.109 1.2 
53 BUB1 budding uninhibited by ben BUB1 0.92 0.006 1.60E-04 0.043 1.8 
54 asp (abnormal spindle) homolog, ASPM 0.91 0.002 400E-OS 0.026 2.4 
55 karyopherin alpha 2 (RAG cohort KPNA2 0.91 0.008 2.40E-04 0.OS6 1.9 
56 family with sequence similarity 83, FAM83D 0.91 0.006 1.60E-04 0.043 1.S 
57 sema domain, immunoglobulin do SEMMD 0.90 0.030 9.20E-04 0.1SS 1.4 
58 cell division cycle associated 2 CDCA2 0.90 0.008 2.40E-04 0.056 1.3 
59 shugoshin-like 2 (S. pombe) SGOL2 0.89 0.010 2.80E-04 0.063 1.6 
60 v-myc myelocytomatosis viral onc MYC 0.89 0.01S 4.40E-04 0.089 1.9 
61 cyclin F CCNF 0.89 0.007 2.00E-04 0.049 1.3 
62 cell division cycle 25 homolog B ( CDC25B 0.89 0.008 2.40E-04 0.056 1.4 
63 PSlliovirus receptor related immun PVRIG 0.87 0.006 1.60E-04 0.043 1.S 
64 A kinase (PRKA) anchor protein 1 AKAP1 0.87 0.019 6.00E-04 0.109 1.3 
65 cytoskeleton associated protein 5 CKAPS 0.8S 0.016 4.80E-04 0.096 1.2 
66 kinesin family member 14 KIF14 0.8S 0.019 6.00E-04 0.109 1.5 
67 kinesin family member 2C KIF2C 0.84 0.008 2.40E-04 0.OS6 1.6 
68 peroxisome proliferator-activated PPRC1 0.84 0.017 S.20E-04 0.101 12 
69 ~erm associated antigen 5 SPAGS 0.84 0.017 S.20E-04 0.101 1.2 
70 metadherin MTDH 0.84 0.034 0.0010799S7 0.173 1.6 
43 
TABLE 1. RADIATION REPRESSED GENES IN RESPONSE TO 5 Gv JR. 
This table lists the transcripts repressed after radiation in response to a 5 Gy IR 5 hour exposure. Genes 
were determined to be enriched at a FDR cutoff of ~ 0.05. Genes represented multiple times in this list 
indicate independent measurements from independent probe sets on the array. 
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rank radiation-induced genes symbol Score FOR P value Q Value Fold Change 
1 pleckstrin homology-like domain, family PHLDA3 -3.05 0.0019 0.0000 0.0259 2.14 
2 protein phosphatase 10 magnesium-dep PPM1D -2.34 0.0019 00000 0.0259 2.40 
3 damage-specific DNA binding protein 2, DDB2 -2.32 0.0019 00000 0.0259 2.43 
4 TP53 regulated inhibitor of apoptosis 1 TRIAP1 -2.18 0.0019 0.0000 0.0259 2.79 
5 BTB (POZ) domain containing 10 BTBD10 -2.12 0.0019 0.0000 0.0259 1.53 
6 growth arrest and DNA-damage-inducibl GADD45A -212 0.0019 0.0000 0.0259 2.49 
7 plexin B2 PLXNB2 -2.03 0.0019 0.0000 0.0259 2.50 
8 xeroderma pigmentosum, complementati XPC -2.03 0.0019 00000 0.0259 2.26 
9 chromosome 8 open reading frame 38 C80rf38 -1.98 0.0019 0.0000 0.0259 2.26 
10 F -box protein 22 FBX022 -1.97 0.0019 0.0000 0.0259 2.35 
11 mitochondrial ribosomal protein L49 MRPL49 -1.93 0.0019 0.0000 0.0259 1.52 
12 sestrin 1 SESN1 -1.84 0.0019 0.0000 0.0259 2.62 
13 chromosome 1 open reading frame 183 C10rf183 -1.82 0.0019 0.0000 0.0259 1.42 
14 zinc finger, matrin type 3 ZMAT3 -1.80 0.0019 00000 0.0259 2.18 
15 cyclin-dependent kinase inhibitor 1A (p21 CDKN1A -1.76 0.0019 0.0000 0.0259 2.88 
16 zinc finger protein 79 ZNF79 -1.70 0.0019 00000 0.0259 1.42 
17 MAD1 mitotic arrest deficient-like 1 (yeas MAD1L1 -1.67 0.0019 0.0000 0.0259 1.76 
18 tripartite motif-containing 22 TRIM22 -1.64 0.0019 0.0000 0.0259 1.59 
19 ferredoxin reductase FDXR -1.64 0.0019 0.0000 0.0259 3.74 
20 Ipolymerase (DNA directed), eta POLH -1.64 0.0019 0.0000 0.0259 1.58 
21 F-box protein 22 FBX022 -1.57 0.0019 0.0000 0.0259 2.26 
22 Notch homolog 1, translocation-associat NOTCH1 -1.57 0.0019 0.0000 0.0259 1.37 
23 zinc finger protein 337 ZNF337 -1.54 0.0019 0.0000 0.0259 1.44 
24 Fas (TNF receptor superfamily, member FAS -1.53 0.0034 0.0001 0.0280 1.90 
25 carboxypeptidase M CPM -1.52 0.0019 0.0000 0.0259 1.85 
26 NA NA -1.51 0.0019 0.0000 0.0259 2.06 
27 NA NA -1.49 0.0019 0.0000 0.0259 2.20 
28 glutaminase 2 (liver, mitochondrial) GLS2 -1.49 0.0019 0.0000 0.0259 2.00 
29 NA NA -1.49 0.0019 0.0000 0.0259 1.59 
30 protein kinase, AMP-activated, beta 1 no PRKAB1 -1.48 0.0019 0.0000 0.0259 1.49 
31 NA NA -1.47 0.0019 0.0000 0.0259 1.52 
32 carboxypeptidase M CPM -1.41 0.0019 00000 0.0259 3.36 
33 zinc finger protein 79 ZNF79 -1.40 0.0019 00000 0.0259 1.48 
34 ankyrin repeat, family A (RFXANK-like), ANKRA2 -1.39 0.0019 0.0000 0.0259 1.99 
35 transmembrane protein 168 TMEM168 -1.39 0.0019 0.0000 0.0259 2.00 
36 biogenesis of lysosome-related organelle BLOC1S2 -1.38 0.0019 0.0000 0.0259 2.61 
37 von Willebrand factor C and EGF domain VWCE -1.36 0.0019 0.0000 0.0259 1.65 
38 transmembrane protein 142C TMEM142C -1.36 0.0019 0.0000 0.0259 1.65 
39 Fas (TNF receptor superfamily, member FAS -1.36 0.0034 0.0001 0.0280 2.29 
40 casein kinase 1, gamma 1 CSNK1G1 -1.35 0.0019 0.0000 0.0259 1.58 
41 damage-regulated autophagy modulator DRAM -1.33 0.0019 0.0000 0.0259 1.97 
42 F-box protein 22 FBX022 -1.33 0.0034 0.0001 0.0280 2.21 
43 breast cancer metastasis-suppressor 1-li BRMS1L -1.32 0.0019 0.0000 0.0259 1.50 
44 chromosome 12 open reading frame 5 C120rf5 -1.32 0.0019 0.0000 0.0259 3.24 
45 vacuolar protein sorting 33 homolog B (Y' VPS33B -1.30 0.0019 0.0000 0.0259 1.17 
46 transmembrane 7 superfamily member 3 TM7SF3 -1.29 0.0019 0.0000 0.0259 1.51 
47 RNA binding motif protein 14 RBM14 -1.28 0.0019 0.0000 0.0259 1.45 
48 sestrin 2 SESN2 -1.28 0.0019 0.0000 0.0259 2.46 
49 activating signal cOintegrator 1 complex s ASCC3 -1.27 0.0034 0.0001 0.0280 1.77 
50 coiled-coil domain containing 90B CCDC90B -1.27 0.0045 0.0001 0.0365 2.27 
51 CLP1, cleavage and polyadenylation fact CLP1 -1.26 0.0019 00000 0.0259 1.32 
52 aprataxin APTX -1.25 0.0019 0.0000 0.0259 1.46 
53 leucine-rich repeats and death domain cc LRDD -1.24 0.0034 0.0001 0.0280 1.26 
54 FtsJ homolog 2 (E. coli) FTSJ2 -1.24 0.0019 0.0000 0.0259 1.47 
55 leucine-rich repeats and death domain cc LRDD -1.23 0.0019 0.0000 0.0259 1.76 
56 RAD51 homolog C (S. cerevisiae) RAD51C -1.23 0.0034 0.0001 0.0280 1.61 
57 chromosome 13 open reading frame 31 C130rf31 -1.22 0.0034 0.0001 0.0280 1.39 
58 astrotactin 2 ASTN2 -1.21 0.0019 0.0000 0.0259 1.52 
59 phosphodiesterase 4B, cAMP-specific (p PDE4B -1.20 0.0045 0.0001 0.0365 1.85 
60 astrotactin 2 ASTN2 -1.20 0.0034 0.0001 0.0280 1.45 
61 transducer of ERBB2, 1 TOB1 -1.18 0.0045 0.0001 0.0365 1.71 
62 NA NA -118 0.0034 0.0001 0.0280 2.40 
63 zinc finger protein 90 homolog (mouse) ZFP90 -118 0.0019 00000 0.0259 1.47 
64 papilin, proteoglycan-like sulfatedglycop PAPLN -118 0.0019 00000 0.0259 1.86 
65 proliferating cell nuclear antigen PCNA -1.17 0.0045 0.0001 0.0365 1.86 
66 polymerase (DNA directed), eta POLH -116 0.0034 0.0001 0.0280 1.71 
67 cyclin G1 CCNG1 -1.16 0.0034 0.0001 0.0280 1.68 
68 proline-serine-threonine phosphatase int PSTPIP2 -1.15 0.0045 0.0001 0.0365 1.41 
69 solute carrier family 7 (cationic amino aci SLC7A6 -1.14 0.0019 0.0000 0.0259 1.40 
70 a')'l-Coenzvme A binding domain contai ACBD6 -1.12 0.0034 0.0001 0.0280 1.36 
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rank radiation-induced genes symbol Score FOR Feature F Q Value Fold Change 
71 Fas (TNF receptor superfamily, member FAS -1.12 0.0058 0.0002 0.0426 2.02 
72 chromosome 1 open reading frame 183 C10rf183 -1.12 0.0019 0.0000 0.0259 1.27 
73 GTP binding protein 2 GTPBP2 -1.11 0.0045 0.0001 0.0365 1.26 
74 chromosome 11 open reading frame 24 C110rf24 -1.11 0.0034 0.0001 0.0280 1.35 
75 IBR domain containing 3 IBRDC3 -1.11 0.0058 0.0002 0.0426 1.79 
76 RAP2B, member of RAS oncogene famil RAP2B -1.10 0.0108 0.0003 0.0700 1.39 
77 solute carrier family 35 (UDP-glucuronic SLC35D1 -1.10 0.0019 0.0000 0.0259 1.72 
78 interferon stimulated exonuclease gene 2 ISG20L1 -1.09 0.0019 0.0000 0.0259 1.54 
79 AP2 associated kinase 1 AAK1 -1.09 0.0034 0.0001 0.0280 1.38 
80 G protein-coupled receptor 109B GPR109B -1.08 0.0070 0.0002 0.0492 1.60 
81 FtsJ homolog 2 (E. coli) FTSJ2 -1.08 0.0070 0.0002 0.0492 1.67 
82 transmembrane 7 superfamily member 3 TM7SF3 -1.07 0.0045 0.0001 0.0365 2.30 
83 regulator of G-protein signalling 16 RGS16 -1.07 0.0019 0.0000 0.0259 1.93 
84 breast cancer metastasis-suppressor 1-1i BRMS1L -1.06 0.0045 0.0001 0.0365 1.20 
85 ribosomal protein S27 -like RPS27L -1.06 0.0108 0.0003 0.0700 1.71 
86 major histocompatibility complex, class 1- MR1 -1.06 0.0019 0.0000 0.0259 1.29 
87 protein tyrosine phosphatase type IVA, m PTP4A1 -1.05 0.0034 0.0001 0.0280 1.30 
88 TAF3 RNA polymerase II, TAT A box bind TAF3 -1.05 0.0045 0.0001 0.0365 1.28 
89 transmembrane protein 168 TMEM168 -1.04 0.0019 0.0000 0.0259 1.59 
90 etoposide induced 2.4 mRNA EI24 -1.04 0.0034 0.0001 0.0280 1.48 
91 ribonucleotide reductase M2 B (TP53 ind RRM2B -1.04 0.0045 0.0001 0.0365 3.07 
92 catenin (cadherin-associated protein), del CTNND1 -1.04 0.0019 0.0000 0.0259 1.37 
93 cleavage stimulation factor, 3' pre-RNA, CSTF3 -1.04 0.0070 0.0002 0.0492 1.36 
94 CDP-diacylglycerol synthase (phosphatid CDS2 -1.03 0.0045 0.0001 0.0365 1.26 
95 tumor necrosis factor receptor superfamil TNFRSF10B -1.03 0.0108 0.0003 0.0700 2.06 
96 carboxypeptidase M CPM -1.03 0.0134 0.0004 0.0819 3.45 
97 Ilysosomal-associated membrane protein LAMP3 -1.03 0.0045 0.0001 0.0365 1.61 
98 chromosome 1 open reading frame 183 C10rf183 -1.03 0.0082 0.0002 0.0558 1.34 
99 carboxypeptidase M CPM -1.02 0.0019 0.0000 0.0259 1.72 
100 ribosomal protein S27-like RPS27L -1.02 0.0058 0.0002 0.0426 1.87 
101 zinc finger protein 654 ZNF654 -1.02 0.0034 0.0001 0.0280 1.36 
102 sestrin 2 SESN2 -1.01 0.0082 0.0002 0.0558 1.84 
103 activating signal cointegrator 1 complex s ASCC3 -1.00 0.0034 0.0001 0.0280 1.35 
104 BCL2 binding component 3 BBC3 -1.00 0.0082 0.0002 0.0558 1.34 
105 proliferating cell nuclear antigen PCNA -0.99 0.0034 0.0001 0.0280 1.15 
106 polo-like kinase 3 (Drosophila) PLK3 -0.99 0.0045 0.0001 0.0365 1.36 
107 zinc finger, FYVE domain containing 1 ZFYVE1 -0.99 0.0034 0.0001 0.0280 1.36 
108 solute carrier family 35 (UDP-glucuronic SLC35D1 -0.98 0.0019 0.0000 0.0259 1.54 
109 IBR domain containing 3 IBRDC3 -0.97 0.0193 0.0006 0.1092 2.24 
110 RAB, member of RAS oncogene family-Ii RABL2B -0.97 0.0070 0.0002 0.0492 1.19 
111 DCP1 decapping enzyme homolog B (S. DCP1B -0.97 0.0045 0.0001 0.0365 1.83 
112 chromosome 3 open reading frame 1 C3orf1 -0.97 0.0045 0.0001 0.0365 1.61 
113 Fas (TNF receptor superfamily, member FAS -0.96 0.0082 0.0002 0.0558 2.13 
114 Rab geranylgeranyltransferase, alpha su RABGGTA -0.96 0.0045 0.0001 0.0365 1.48 
115 nudix (nucleoside diphosphate linked moi NUDT15 -0.95 0.0108 0.0003 0.0700 1.51 
116 CD70 molecule CD70 -0.95 0.0134 0.0004 0.0819 1.51 
117 major histocompatibility complex, class 1- MR1 -0.95 0.0058 0.0002 0.0426 1.19 
118 carcinoembryonic antigen-related cell ad CEACAM1 -0.95 0.0082 0.0002 0.0558 1.40 
119 Iphosphohistidine phosphatase 1 PHPT1 -0.94 0.0019 0.0000 0.0259 1.34 
120 GPI deacylase PGAP1 -0.94 0.0019 0.0000 0.0259 1.27 
121 NA NA -0.94 0.0097 0.0003 0.0630 1.21 
122 annexin A4 ANXA4 -0.93 0.0221 0.0007 0.1215 1.35 
123 tumor necrosis factor (ligand) superfamily TNFSF9 -0.93 0.0134 0.0004 0.0819 1.69 
124 syntaxin 6 STX6 -0.92 00108 0.0003 0.0700 1.32 
125 zinc finger CCCH-type, antiviral 1 ZC3HAV1 -0.92 0.0034 0.0001 0.0280 1.19 
126 ribosomal protein S6 kinase, 90kDa, poly RPS6KA1 -0.91 0.0123 0.0004 0.0764 1.42 
127 potassium intermediate/small conductan KCNN3 -0.91 0.0058 0.0002 0.0426 1.41 
128 tripartite motif-containing 32 TRIM32 -0.90 0.0019 0.0000 0.0259 1.30 
129 Iysophospholipase 3 (lysosomal phospho LYPLA3 -0.90 0.0082 0.0002 0.0558 1.18 
130 NA NA -0.90 0.0019 0.0000 0.0259 1.30 
131 damage-specific DNA binding protein 2, DDB2 -0.90 0.0045 0.0001 0.0365 1.56 
132 RAN binding protein 10 RANBP10 -0.90 0.0134 0.0004 0.0819 1.10 
133 TP53 activated protein 1 TP53AP1 -0.89 0.0058 0.0002 0.0426 1.47 
134 Mdm2, transformed 3T3 cell double minu MDM2 -0.89 0.0149 0.0004 0.0891 1.98 
135 immediate early response 5 IER5 -0.88 0.0193 0.0006 0.1092 1.98 
136 transmembrane 7 superfamily member 3 TM7SF3 -0.88 0.0184 0.0006 0.1062 1.87 
137 cell growth regulator with ring finger dom CGRRF1 -0.88 0.0045 0.0001 0.0365 1.33 
138 transmembrane 7 superfamily member 2 TM7SF2 -0.88 0.0070 0.0002 0.0492 1.38 
139 Iproline rich 14 PRR14 -0.87 0.0108 0.0003 0.0700 1.10 
140 GPI deacylase PGAP1 -0.87 0.0134 0.0004 0.0819 1.22 
46 
rank radiation-induced genes symbol Score FDR Feature F Q Value Fold Change 
141 galactose-3-0-sulfotransferase 4 GAL3ST4 -0.87 0.0123 0.0004 0.0764 1.27 
142 E2F transcription factor 7 E2F7 -0.87 0.0058 0.0002 0.0426 2.68 
143 solute carrier family 30 (zinc transporter), SLC30A1 -0.86 0.0173 0.0005 0.1008 1.57 
144 TP53 activatedjlfotein 1 TP53AP1 -0.86 0.0058 0.0002 0.0426 1.47 
145 tumor protein p53 inducible protein 3 TP5313 -0.86 0.0019 0.0000 0.0259 1.69 
146 apolipoprotein B mRNA editing enzyme, APOBEC3G -0.86 0.0184 0.0006 0.1062 1.65 
147 inositol polyphosphate-1-phosphatase INPP1 -0.86 0.0108 0.0003 0.0700 1.65 
148 chromosome 10 open reading frame 10 C100rf10 -0.86 0.0232 0.0007 0.1264 1.30 
149 scribbled homolog (Drosophila) SCRIB -0.86 0.0298 0.0009 0.1554 1.39 
150 sorbitol dehydrogenase SORD -0.86 0.0123 0.0004 0.0764 1.27 
151 suppressor of variegation 4-20 homolog 1 SUV420H1 -0.85 0.0108 0.0003 0.0700 1.35 
152 dermatan 4 sulfotransferase 1 D4ST1 -0.85 0.0082 0.0002 0.0558 1.27 
153 zinc finger protein 337 ZNF337 -0.85 0.0320 0.0010 0.1643 1.20 
154 KlAA1128 KlAA1128 -0.85 0.0108 0.0003 0.0700 1.24 
155 F-box protein 22 FBX022 -0.84 0.0184 0.0006 0.1062 1.25 
156 AP2 associated kinase 1 AAK1 -0.84 0.0184 0.0006 0.1062 1.43 
157 hydroxysteroid dehydrogenase like 2 HSDL2 -0.84 0.0097 0.0003 0.0630 1.37 
158 creatine kinase, mitochondrial 2 (sarcom CKMT2 -0.84 0.0163 0.0005 0.0961 1.18 
159 protein tyrosine phosphatase type IVA, m PTP4A1 -0.84 0.0034 0.0001 0.0280 1.34 
160 apoptotic peptidase activating factor 1 APAF1 -0.84 0.0184 0.0006 0.1062 1.33 
161 leukemia inhibitory factor (cholinergic diff LlF -0.83 0.0289 0.0009 0.1515 1.29 
162 tumor protein p53 inducible nuclear prote TP531NP1 -0.83 0.0070 0.0002 0.0492 2.00 
163 Ras-related associated with diabetes RRAD -0.83 0.0173 0.0005 0.1008 1.22 
164 TP53 activated protein 1 TP53AP1 -0.82 0.0045 0.0001 0.0365 1.52 
165 chromosome 11 open reading frame 24 C110rf24 -0.82 0.0163 0.0005 0.0961 1.40 
166 dynactin 5 (p25) DCTN5 -0.82 0.0184 0.0006 0.1062 1.13 
167 guanidinoacetate N-methyltransferase GAMT -0.82 0.0173 0.0005 0.1008 1.25 
168 thymidylate synthetase TYMS -0.82 0.0207 0.0006 0.1153 1.37 
169 transducer of ERBB2, 1 TOB1 -0.82 0.0407 0.0013 0.1973 1.80 
170 ATG16 autophagy related 16-like 2 (S. c ATG16L2 -0.82 0.0108 0.0003 0.0700 1.25 
171 Tax1 (human T-cell leukemia virus type I TAX1BP3 -0.81 0.0484 0.0016 0.2252 1.48 
172 glutathione peroxidase 1 GPX1 -0.81 0.0298 0.0009 0.1554 1.32 
173 chromosome 1 open reading frame 57 C10rf57 -0.81 0.0070 0.0002 0.0492 1.28 
174 NA NA -0.81 0.0446 0.0015 0.2113 1.67 
175 Pvt1 oncogene homolog, MYC activator ( PVT1 -0.81 0.0393 0.0012 0.1939 1.27 
176 inositoI1,4,5-triphosphate receptor, type ITPR2 -0.81 0.0407 0.0013 0.1973 2.01 
177 capicua homolog (Drosophila) CIC -0.81 0.0419 0.0014 0.2016 1.18 
178 interleukin 27 receptor, alpha IL27RA -0.81 0.0310 0.0010 0.1597 1.27 
179 phosphatidylinositol 4-kinase, catalytic, b PIK4CB -0.80 0.0262 0.0008 0.1399 1.32 
180 protein kinase, X-linked PRKX -0.80 0.0207 0.0006 0.1153 1.33 
181 ATP-binding cassette, sub-family A (ABC ABCA5 -0.80 0.0397 0.0013 0.1939 1.27 
182 receptor expressed in lymphoid tissues Ii RELL1 -0.80 0.0173 0.0005 0.1008 1.57 
183 vacuolar protein sorting 24 homolog (S. c VPS24 -0.79 0.0232 0.0007 0.1264 1.25 
184 chromosome 1 open reading frame 121 C10rf121 -0.79 0.0397 0.0013 0.1939 1.29 
185 SMEK homolog 1, suppressor of mek1 ( SMEK1 -0.79 0.0173 0.0005 0.1008 1.48 
186 RAD51 homolog G (S. cerevisiae) RAD51C -0.79 0.0529 0.0018 0.2412 1.34 
187 growth differentiation factor 15 GDF15 -0.79 0.0019 0.0000 0.0259 3.23 
188 WASfWASL interacting protein family, m WIPF2 -0.78 0.0426 0.0014 0.2041 1.18 
189 carboxymethylenebutenolidase homolog CMBL -0.78 0.0310 0.0010 0.1597 2.21 
190 Ras-related associated with diabetes RRAD -0.78 0.0495 0.0017 0.2289 1.42 
191 SERTA domain containing 1 SERTAD1 -0.78 0.0320 0.0010 0.1643 1.34 
192 abl1ydrolase domain containi'lg4 ABHD4 -0.78 0.0354 0.0011 0.1778 1.17 
193 hypothetical gene supported by BC02419 LOC400099 -0.78 0.0467 0.0016 0.2189 1.17 
194 transmembrane protein 30A TMEM30A -0.78 0.0298 0.0009 0.1554 1.51 
195 myeloid leukemia factor 2 MLF2 -0.78 0.0393 0.0012 0.1939 1.32 
196 phosphodiesterase 4B, cAMP-specific (p PDE4B -0.78 0.0184 0.0006 0.1062 1.68 
197 activating transcription factor 3 ATF3 -0.78 0.0426 0.0014 0.2041 1.79 
198 RAP2B, member of RAS oncogene famil RAP2B -0.78 0.0354 0.0011 0.1778 1.58 
199 casein kinase 1, gamma 1 CSNK1G1 -0.78 0.0221 0.0007 0.1215 1.25 
200 motile sperm domain containing 1 MOSPD1 -0.78 0.0320 0.0010 0.1643 1.24 
201 SEC22 vesicle trafficking protein homolo SEC22A -0.77 0.0446 0.0015 0.2113 1.11 
202 cytochrome P450, family 4, subfamily F, CYP4F3 -0.77 0.0456 0.0015 0.2150 1.16 
203 hydroxysteroid (17-beta) dehydrogenase HSD17B7P2 -0.77 0.0741 0.0026 0.3138 1.72 
204 actin, alpha 2, smooth muscle, aorta ACTA2 -0.77 0.0397 0.0013 0.1939 1.52 
205 transmembrane protein 68 TMEM68 -0.77 0.0565 0.0019 0.2542 1.74 
206 NA NA -0.77 0.0484 0.0016 0.2252 1.14 
207 tripartite motif-containing 38 TRIM38 -0.77 0.0495 0.0017 0.2289 1.28 
208 nucleolar protein 14 NOL14 -0.77 0.0426 0.0014 0.2041 1.20 
209 sestrin 1 SESN1 -0.76 0.0593 0.0020 0.2647 1.17 
210 Iproline rich 14 PRR14 -0.76 0.0193 0.0006 0.1092 1.18 
211 SMAD family member 5 SMAD5 -0.76 0.0354 0.0011 0.1778 1.71 
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TABLE 2. RADIATION-INDUCED GENES AFTER IR. 
This table lists the transcripts induced after radiation in response to a 5 Gy IR 5 hour exposure. Genes 
were determined to be enriched at a FDR cutoff of ~ 0.05. Genes represented mUltiple times in this list 
indicate independent measurements from independent probe sets on the array. 
GO Categories Enriched in Irradiated Samples (i.e. radiation-induced) 
Category Name Name SIZE EnrichmentScore Normalized ES NOM.p.val FDR.q.val 
Biological 
GO:0030203 Process glycosaminoglycan metabolism 34 -0.61 -2.04 0.00 0.00 
Biological 
GO:0006022 Process aminoglycan metabolism 35 -0.60 -2.02 0.00 0.00 
Biological 
GO:0006029 Process proteoglycan metabolism 24 -0.61 -1.92 0.00 0.01 
Biological 
GO:0006790 Process sulfur metabolism 54 -0.48 -1.89 0.00 0.01 
Biological 
GO:0008285 Process negative regulation of cell proliferation 130 -0.42 -1.88 0.00 0.01 
Biological 
GO:0007050 Process cell cycle arrest 56 -0.52 -1.80 0.00 0.02 
Biological 
GO:0042157 Process lipoprotein metabolism 38 -0.51 -1.77 0.00 0.03 
Biological 
GO:0045786 Process negative regulation of progression through cell c: 133 -0.41 -1.73 0.00 0.04 
Biological 
GO:0007259 Process JAK-STA T cascade 29 -0.48 -1.72 0.00 0.04 
Biological 
GO:0007179 Process transforming growth factor beta receptor signalin 30 -0.51 -1.71 0.01 0.04 
Biological 
GO:0006919 Process caspase activation 24 -0.57 -1.71 0.01 0.04 
Biological 
GO:0051345 Process positive regulation of hydrolase activity 24 -0.57 -1.71 0.01 0.03 
Biological 
GO:0043280 Process positive regulation of caspase activity 24 -0.57 -1.71 0.01 0.03 
Biological 
GO:0044272 Process sulfur compound biosynthesis 28 -0.52 -1.71 0.00 0.03 
Cellular 
GO:0015630 Component microtubule cytoskeleton 200 0.48 1.95 0.00 0.02 
Cellular 
GO:0005819 Component spindle 48 0.66 1.92 0.00 0.01 
Cellular 
GO:0000785 Component chromatin 105 0.52 1.89 0.00 0.01 
Cellular 
GO:0005875 Component microtubule associated complex 83 0.46 1.88 0.00 0.01 
Cellular 
GO:0005874 Component microtubule 145 0.45 1.83 0.00 0.02 
Cellular 
GO:0000775 Component chromosome, peri centric region 29 0.73 1.71 0.00 0.04 
Cellular 
GO:0000786 Comoonent nucleosome 47 0.52 1.69 0.03 0.04 
Molecular 
GO:0003777 Function microtubule motor activity 56 0.58 2.12 0.00 0.00 
Molecular 
GO:0003774 Function motor activity 119 0.38 1.73 0.00 0.09 
Molecular 
GO:0004725 Function protein tyrosine phosphatase activity 71 0.41 1.70 0.00 0.10 
Molecular 
GO:0004540 Function ribonuclease activity 49 0.48 1.63 0.01 0.18 
Molecular 
GO:0003682 Function chromatin binding 40 0.53 1.60 0.02 0.19 
Molecular 
GO:0005200 Function structural constituent of cytoskeleton 81 0.38 1.56 0.02 0.27 
Molecular 
GO:0008138 Function protein tyrosine/serine/threonine phosphatase ac 33 0.42 1.49 0.02 0.53 
TABLE 3. ENRICHMENT OF GO CATEGORIES FOR THE RADIATION-INDUCED GENES. 
Gene set enrichment was calculated using GSEA for GO categories strongly associated with the irradiated 
samples in comparison to the unirradiated samples. The Enrichment Score (ES) was calculated using the 
Signal2Noise test statistic (see Methods) and 1000 permutations were used for each analysis. 
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GO Categories Enriched in Non-irradiated samples (Le. radiation-repressed) 
Category Name SIZE EnrichmentScore Normalized ES NOM.p.val FDR.q.val 
Biological 
GO:0007017 Process microtubule-based process 116 0.60 2.09 0.00 0.00 
Biological 
GO:0007010 Process cytoskeleton organization and biogenesis 311 0.46 2.03 0.00 0.00 
Biological 
GO:0007018 Process microtubule-based movement 68 0.55 2.01 0.00 000 
Biological 
GO:0030705 Process cytoskeleton-dependent intracellular transport 72 0.53 1.97 0.00 0.00 
Biological 
GO:0000279 Process M phase 162 0.64 1.97 0.00 000 
Biological 
GO:0000226 Process microtubule cytoskeleton organization and bioge 47 0.68 1.95 0.00 0.00 
Biological 
GO:0051258 Process protein polymerization 35 0.58 1.86 0.00 0.01 
Biological 
GO:0051301 Process cell division 143 0.62 1.85 0.00 0.01 
Biological 
GO:0000087 Process M phase of mitotic cell cycle 128 0.68 1.85 0.00 0.01 
Biological 
GO:0007059 Process chromosome segregation 23 0.72 1.84 0.00 0.01 
Biological 
GO:0007067 Process mitosis 126 0.68 1.84 0.00 0.01 
Biological 
GO:0000278 Process mitotic cell cycle 188 0.59 1.76 0.00 0.03 
Cellular 
Component none were significant 
Molecular 
Function none were sianificant 
TABLE 4. ENRICHMENT OF GO CATEGORIES IN THE UNIRRADIATED SAMPLES. 
Gene set enrichment was calculated using GSEA for GO categories strongly associated with the 
unirradiated samples in comparison to the irradiated samples. The Enrichment Score (ES) was calculated 
using the Signal2Noise test statistic (see Methods) and 1000 permutations were used for each analysis. 
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Dataset Phenotype Enriched for RI Enriched for RR 
Breast cancer (van de Vijver 2002) outcome 0.434, 0.442 0.000, 0.001 
Breast cancer (van de Vijver 2002) ER status 0.286,0.310 0.001, 0.006 
Breast cancer (West 2001) ER status 0.789, 1 0.004, 0.006 
Breast cancer (van de Vijver 2002) BRCA 112 status 0.166,0.455 0.024,0.013 
Lung (Beer 2002) outcome 0.155, 0.191 0.315,0.792 
Lung (Bhatacharjee 2001) outcome 0.861, 0.811 0.678, 1 
Lymphoma (Monti 2001) outcome 0.230, 0.451 0.502, 0.453 
Glioma (Nutt 2003) outcome 0.623, 0.563 0.567, 1 
Medulloblastoma (Pomeroy 2002) outcome 0.316,0.307 0.157,0.202 
Hepatocarcinoma (Iizuka 2003) outcome 0.519, 0.605 0.453, 1 
Multiple cancers (Ramaswamy P53 status 0.000, 0.006 0.113,0.169 2001) 
TABLE 5. ENRICHMENT OF CLINICAL PARAMETERS IN RADIATION-INDUCED AND RADIATION-REPRESSED GENE SETS BY 
GSEA. 
We tested for enrichment of Radiation Induced (RI) or Radiation Repressed (RR) gene sets with respect to 
clinical parameters in a panel of tumor data sets, assessed by the GSEA tool. The pairs of numerical values 
in each row correspond to: nominal p-value, q-value. Data tested were curated from a number of 
expression datasets from multiple cancers. The clinical traits tested were comprised of outcome in 
multiple cancer types (BEER et 01. 2002; BHATIACHARJEE et 01. 2001; MONTI et 01. 2005; NUTI et 01. 2003; 
POMEROY et 01.2002; SINGH et 01. 2002; VAN DE VINER et 01. 2002), estrogen receptor status in breast cancers 
(VAN DE VINER et 01. 2002; WEST et 01.2001), Brca1 status in breast cancer (VAN 'TVEER et 01.2002), and P53 
status in multiple cancer cell lines (RAMASWAMY et 01. 2001). Radiation-induced (RI) and radiation-
repressed (RR) genes from this study were used as bait for the GSEA program (SUBRAMANIAN et 01. 2005) 
in testing for correlation with the clinical parameters described above. For the GSEA settings, we used the 
Signal2Noise algorithm, normalization method was meandiv, permutations were done by phenotype, the 
scoring scheme was weighted, and 1000 permutations were used for each analysis. Results were 
considered to be significant (and displayed in boldface) if both the p-value ::; 0.05 & the FDR q-value ::; 
0.05. For breast cancers, clinical outcome, ER- status, Her2-, and BRCA1/2 mutant status were significantly 
associated with the RR signature. The RI signature showed correlation with wildtype P53 status. 
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Rlgene p-value p53 regulated? reference 
BLOC1S2 0 not reported 
BRMS1L 0 not reported 
BTBD10 0 not reported 
C12orf5 0 yes Jen, Cancer Res. 2005 65:7666-73 
C8orf38 0 not reported 
DRAM 0 yes Creighton, Cell 2006, 121-34 
FBX022 0 not reported 
FTSJ2 0 not reported 
LRDD 0 yes Genome BioI. 2006; 7(3): R25. 
NOTCH1 0 yes Yugawa MCB 2007 
PPM1D 0 yes Choi, Genomics 2000 
TRIAP1 0 yes Park Cancer Res. 2005 65(4):1197-206. 
APTX 1.00E-04 not reported 
SESN2 2.00E-04 yes Budanov, Oncogene 2002, 21 :6017-31. 
XPC 5.00E-04 yes Genome BioI. 2006; 7(3): R25. 
RBM14 0.001 not reported 
ZNF337 0.001 not reported 
CSNK1G1 0.0012 yes JCB, Volume 173, Number 4,533-544 
MAD1L1 0.0021 yes Chun J Bioi Chern. 2003 
TRIM22 0.0029 yes Genome Bioi. 2006; 7(3): R25. 
CDKN1A 0.0043 yes Jen, Cancer Res. 2005 65:7666-73 
TMEM142C 0.0084 not reported 
PHLDA3 0.0128 yes Jen, Cancer Res. 2005 65:7666-73 
C1orf183 0.0276 not reported 
VPS33B 0.0281 not reported 
CPM 0.0361 not reported 
PRKAB1 0.0365 yes Jen, Cancer Res. 2005 65:7666-73 
GLS2 0.0599 yes Genome BioI. 2006; 7(3): R25. 
ZMAT3 0.0602 yes Genome BioI. 2006; 7(3): R25. 
FDXR 0.0793 yes Liu & Chen; Oncogene 2002 
ZNF79 0.0912 not reported 
TM7SF3 0.1251 not reported 
POLH 0.1358 yes Liu & Chen MCB 2006 
DDB2 0.1791 yes Barenco Genome BioI. 2006; 7(3): R25. 
MRPL49 0.286 yes Yang, J Invest. Derm. 2006 :2490-506. 
VWCE 0.4255 not reported 
ANKRA2 0.5336 not reported 
GADD45A 0.6555 yes Genome BioI. 2006; 7(3): R25. 
TMEM168 0.7914 not reported 
SESN1 0.8738 yes Genome BioI. 2006; 7(3): R25. 
ASTN2 0.8815 yes Wei, Cell 124, pp 207-219 
TABLE 6. P53-DEPENDENT TARGETS IN THE RI SET. 
Only a subset of genes in the RI gene set are known to be targets of p53. For the 41 RI genes overlapping 
with the Loi et al. breast tumor dataset (LOI et 01. 200n we list the p-value for differential expression 
between the good- and poor-outcome clusters, along with information on whether gene expression is 
51 
known to be driven by p53. Genes with significant p-values (indicated by boldface text) showing 
differential expression between the two clusters are hypothesized to playa role in driving the clustering. 
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Gene Symbol t-test p-value q-value 
MMP23B -0.181 0 0.002 
DPAGT1 -0.26 0 0.009 
SPTBN1 -0.26 0 0.012 
LPP -0.311 0 0.014 
DCTN3 -0.294 0 0.014 
ZNF318 -0.282 0 0.014 
GTF2H1 -0.27 0 0.014 
BTN2A1 -0.27 0 0.014 
DDX12 -0.261 0 0.014 
N/A -0.248 0 0.014 
N/A -0.238 0 0.014 
CLTA -0.238 0 0.014 
GALNT1 -0.237 0 0.014 
DNMT1 -0.235 0 0.014 
GOLGA4 -0.23 0 0.014 
STK38 -0.212 0 0.014 
FRG1 -0.199 0 0.014 
EBP -0.183 0 0.014 
LGALS4 -0.182 0 0.014 
MZF1 -0.181 0 0.014 
PLOD2 -0.178 0 0.014 
EIF1AP1 -0.176 0 0.014 
AMPD2 -0.163 0 0.014 
PA2G4 -0.162 0 0.014 
PTCD31BUB3 -0.286 0 0.015 
ARID5A -0.267 0 0.015 
PRDX1 -0.266 0 0.015 
CASR -0.263 0 0.015 
HIST2H2BE -0.257 0 0.015 
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SNRPD2 -0.245 0 0.015 
N/A -0.242 0 0.015 
GSTM5 -0.241 0 0.015 
ARSB -0.24 0 0.015 
ECHS1 -0.237 0 0.015 
IGHG11EPC1 -0.225 0 0.015 
PIM1 -0.224 0 0.015 
LOC728643 -0.219 0 0.015 
LSS -0.218 0 0.015 
GNB2L 1 -0.218 0 0.015 
SERPINB1 -0.218 0 0.015 
HLA-DOA -0.215 0 0.015 
IREB2 -0.202 0 0.015 
SLC31A2 -0.196 0 0.015 
N/A -0.186 0 0.015 
KATNB1 -0.177 0 0.015 
ACY1 -0.176 0 0.015 
SDHDIRHCE -0.175 0 0.015 
C6orf136 -0.175 0 0.015 
RPS6KA3 -0.243 0 0.016 
BCL3 -0.22 0 0.016 
N/A -0.209 0 0.016 
ADD2 -0.199 0 0.016 
TM9SF2 -0.171 0 0.016 
RAB7L 1 -0.253 0 0.017 
N/AINAB1 -0.149 0 0.017 
VASP -0.3 0 0.018 
SCARB1 -0.219 0 0.018 
MEST -0.292 0 0.019 
DCTIEGR1 -0.234 0 0.019 
SLC19A11COL18A1 -0.233 0 0.019 
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N/A -0.203 0 0.019 
LOC1624271N/A -0.189 0 0.019 
U2AF1L4 -0.173 0 0.019 
PAK1 -0.162 0 0.019 
CYP4A 111SLC4A7 -0.273 0.001 0.02 
LOC728913 -0.162 0.001 0.02 
TABLE 7. DIFFERENTIAL EXPRESSION OF GENES IN BREAST TUMOR LINES BEFORE AND AFTER 8 Gv OF IR. 
Differential expression of genes in breast tumor cell lines before and after 8 Gy of IR from a recently 
published dataset from Amundson et al (AMUNDSON et 01. 2008). 
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Univariate Analysis Multivariate Analysis 
Model 1 Model 2 
Hazard P value Hazard P value Hazard P value Ratio Ratio Ratio 
RI Signature 1.1 0.04 1.071 0.170 --- ---
RR Signature 0.896 5.61e-9 0.940 0.030 --- ---
Rad Signature 0.898 2.ge-9 --- --- 0.936 0.021 (RI+RR) 
Age 0.593 0.013 0.652 0.050 0.630 0.033 
Diameter 1.19 0.13 1.033 0.810 1.015 0.910 
Lymph Node (0, 1, 1.12 0.012 1.004 0.970 0.995 0.960 2) 
Tumor Grade (1, 2, 1.98 1.ge-5 1.160 0.460 1.114 0.590 3) 
Vascularl nvasion.13 0.87 0.55 1.741 0.160 1.782 0.140 
VascularlnvasionA 1.90 0.02 2.825 0.140 2.897 0.130 
ER status (1 = pos, 0.334 2.7e-6 0.583 0.069 0.665 0.150 0= neg) 
Mastectomy vs 1.12 0.62 0.983 0.950 1.057 0.820 
conserving therapy 
Chemo or hormonal 0.931 0.75 0.574 0.120 0.582 0.130 therapy 
Wound Response 3.67 9.3e-S 1.382 0.12 1.541 0.230 
TABLE S. ANALYSIS OF RISK FACTORS FOR DEATH IN BREAST CANCER PATIENTS IN THE NKI STUDY. 
Univariate and Multivariate Analysis of risk factors for death in a group of breast cancer patients from the 
Netherland Cancer Institute (VAN DE VIJVER et 01. 2002). The left two columns list hazard ratios and p-values 
from a univariate Cox analysis of survival outcome calculated independently for each parameter. The 
subsequent columns show two variations on a multivariate Cox analysis, using RR and RI sets as 
independent variables with other clinical properties (Modell), and using the combined radiation set with 
the same clinical variables (Model 2). 
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Univariate Analysis Multivariate Analysis 
Model 1 Model 2 
Hazard P value Hazard P value Hazard P value Ratio Ratio Ratio 
RI Signature 1.09 0.005 1.065 0.130 -- --
RR Signature 0.946 3e-5 0.970 0.160 -- --
Rad Signature 0.948 2.6e-5 -- -- 0.954 0.009 (RI+RR) 
Age 1 1 0.99 0.470 0.992 0.540 
Tumor Grade (1, 2, 3) 1.56 0.015 1.043 0.850 1.009 0.970 
Tumor Size ( 0- 8.2) 1.34 0.00012 1.218 0.071 1.182 0.110 
ER status (1 = pos, 0 0.217 0.0097 0.22 0.015 0.232 0.019 
= neg) 
Lymph Node (0, 1) 1.21 0.39 1.110 0.690 1.139 0.620 
TABLE 9. ANALYSIS OF RISK FACTORS FOR DEATH IN BREAST CANCER PATIENTS IN THE LOI ET Ai. STUDY. 
Univariate and Multivariate Analysis of risk factors for death in a group of breast cancer patients from Loi 
et. 01. The left two columns list hazard ratios and p-values from a univariate Cox analysis of survival 
outcome calculated independently for each parameter. The subsequent columns show two variations on 
a multivariate Cox analysis, using RR and RI sets as independent variables with other clinical properties 
(Modell), and using the combined radiation set with the same clinical variables (Model 2). 
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Total Genes Overlap with RR Overlap with RI 
Amsterdam 70-gene 70 1 1 
76-gene 75 0 0 
Wound response 512 1 2 
GGI 97 34 0 
PTEN 246 11 4 
RS 21 3 0 
TABLE 10. OVERLAP OF RR AND RI GENE SIGNATURES WITH OTHER BREAST CANCER OUTCOME SIGNATURES. 
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# of Genes Overlap between Gene set in Signature signature and genes Error Rate Sensitivity 
on the NKI arrays 
Radiation Response 68 (RR) 34(RR)+15(RI) 30.2% 68.4% 
+50(RI) 
Wound Response 512 269 28.7% 75.4% 
70 gene 70 47 34.9% 63.2% 
RS 20 13 28.7% 73.7% 
GGI 94 60 28.7% 73.7% 
76 gene 76 38 29.5% 68.4% 
PTEN 246 104 28.7% 68.4% 
TABLE 11. ERROR RATE AND SENSITIVITY FROM LEAVE-ONE-OUT CROSS VALIDATION. 
Error rate and sensitivity from leave-one-out cross validation analysis of a panel of breast cancer outcome 
signatures for tumor classification using the NKI dataset (VAN DE VINER et 01. 2002). 
Group Index True Survival Predicted Survival #of patients 
1 Good Good (at least 6 out of 7 signature) 51 
2 Good Bad (at least 6 out of 7 signature) 17 
3 Bad Good (at least 6 out of 7 signature) 10 
4 Bad Bad (at least 6 out of 7 signature) 30 
0 3 signature votes for good/bad, while the 21 
other 4 votes for bad/good 
TABLE 12. SEGREGATION OF TUMOR SAMPLES INTO 4 GROUPS BASED ON THEIR CLASSIFICATION BY GENE EXPRESSION 
SIGNATURES. 
Group 1 represents good true survival and correctly classified; group 2 represents good survival and 
incorrectly classified; group 3 is bad survival and incorrectly classified; and group 4 represents bad survival 
and correctly classified. Samples were assigned group 0 if they were not consistently classified as good or 
bad by the panel of expression signatures. 
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HO: no difference HO: no difference 
between Group1 and between Group 2 and 
group 3 group 4 
Age 0.532 0.281 
Diameter 0.922 0.749 
LymphNode 0.991 0.227 
Tumor Grade 0.021 0.293 
Vascular Invasion 0.444 0.289 
ER 0.253 0.066 
Mastectomy vs. conserving 0.283 0.515 
therapy 
Chemo or hormonal 1 1 
therapy 
TABLE 13. P-VALUES FOR THE ASSOCIATION BETWEEN ClINICAL VARIABLES AND GROUP LABElS IN TABLE 12. 
For the first hypothesis tested, the null indicates that there is no difference between the good survival 
samples that were either correctly or incorrectly classified. The second hypothesis is the same but for the 
true bad outcome samples. Tumor grade was significantly different between Groups 1 and 3, and thus 
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FIGURE 1. WESTERN BLOTTING FOR P53 PHOSPHORYLATION IN ATM+/+ AND ATM-/- CELLS. 
A&B. Cell lines of the indicated genotype were treated with the indicated dose of ionizing 
radiation and harvested at the indicated time. Western blotting was performed with an antibody 
recognizing the 515 phosphorylation site on TP53. C. Cell lines of the indicated genotype were 
grown in the presence of the indicated dose of caffeine and subsequently irradiated with 5 Gy of 
IR. Cells were harvested 5 hours after irradiation and Western blotting was performed for 
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FIGURE 2. RADIATION·REPRESSED (RR) OR RADIATION-INDUCED (RI) GENE SIGNATURES CLUSTER BREAST CANCER 
PATIENTS FROM THE NETHERLAND CANCER INSTITUTE ACCORDING TO CLINICAL OUTCOME. 
Panel A shows clustering of tumors in the space of the RR genes. The bars above the heatmap 
indicate clinical variables of tumor grade (black- "poorly differentiated", grey- "intermediate", 
white - "well differentiated"), and ER status (black- positive, white- negative) . Panel B shows K-
M survival analysis for the two clusters separated in A. Panels C&D show clustering analysis and 

































FIGURE 3. RADIATION-REPRESSED (RR) OR RADIATION-INDUCED (RI) GENE SIGNATURES CLUSTER BREAST 
CANCER PATIENTS FROM LOI ET AL. ACCORDING TO CLINICAL OUTCOME. 
Panel A shows clustering of tumors in the space of the RR genes. Panel B shows K-M survival 
ana lysis for the two clusters separated in A. Panels C&O show clustering analysis and survival 
analysis in the space of the RI genes. The bars above the heatmap indicate clinically assessed 
tumor grade (black- "poorly differentiated" I grey- "intermediate" I white - "well 
differentiated"). 
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FIGURE 4. COMPARISON OF TUMOR CLASSIFICATION BY GENE EXPRESSION SIGNATURES. 
Heatmap showing classification of each patient in the NKI dataset based on Cross-Validation 
for all the samples using the panel of gene signatures. Each column represents one patient, 
with yellow indicating classification to the good clinical outcome group and blue representing 
classification to the poor clinical outcome group. The survival time is indicated by the top bars, 
with red indicating a death event. Tumor grade (grade l=white, grade 2 =grey, grade 3=black) 
and ER status (ER- =white, ER+ =black) are also represented by the middle bars. 
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A. Current model for tumorigenesis. 
activation of .------..c:; 
oncogene(s) 
Normal cell • 
proliferation gene 
signature is a 





B. Parallels between DNA damage response and tumorigenesis. 
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FIGURE 5. PARAllElS BETWEEN THE MOLECULAR STAGES OF TUMORIGENESIS AND THE DNA DAMAGE RESPONSE. 
A. Evidence suggests that common forms of cancer may develop through a multistep process that 
may begin with a (dominant) mutation that results in oncogene activation and consequent aberrant 
proliferation. Aberrant proliferation results in replicational stress, leading to DNA double strand 
breaks and activation of the DNA damage response. Ultimately, mutations inactivate the DNA 
damage response, unleashing clonal evolution and tumor progression, leading to poor survival. It 
is well-established that a proliferation cluster of genes predicts outcome in breast cancer. B. 
Exposure to ionizing radiation activates the DNA damage response pathway, resulting in both the 
induction of one set and repression of a second set of genes. Pathway analysis reveals that the 
repressed genes function in cell cycle progression (and overlap with the proliferation cluster 
predicting breast cancer outcomes), whereas the induced genes function in a variety of biochemical 
pathways including checkpoint/cell cycle arrest and apoptosis and do not show significant overlap 
with the proliferation cluster., each plated two times. 
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C HAPT R 3: Results and characterizations from a genome-wide 
screen for L 1/ATM interactions in S. cerevisiae 
Tel1 is the budding yeast ortholog of the mammalian tumor suppressor and DNA 
damage response (DDR) kinase ATM. However, tel1-Ll cells, unlike ATM-deficient cells, 
do not exhibit sensitivity to DNA damaging agents, but do display shortened (but stably 
maintained) telomere lengths. Neither the extent to which Tel1 p functions in the DDR nor 
the mechanism by which Tel1 contributes to telomere metabolism is well-understood. To 
address the first question, we present the results from a comprehensive genome-wide 
screen for genetic interactions with tel1-Ll that cause sensitivity to MMS and/or ionizing 
radiation, along with follow-up characterizations of the 13 interactions yielded by this 
screen. Surprisingly, many of the tel1-Ll interactions that confer DNA damage sensitivity 
also exacerbate the short telomere phenotype, suggesting a connection between these 
two phenomena. Restoration of normal telomere length in the tel1-Ll xxx-Ll mutants 
results in only minor suppression of the DNA damage sensitivity, demonstrating that the 
sensitivity of these mutants must also involve mechanisms independent of telomere 
length. In support of a model for increased replication stress in the tel1-Ll xxx-Ll mutants, 
we show that depletion of dNTP pools through pre-treatment with hydroxyurea renders 
tel1-Ll cells (but not wild-type) MMS-sensitive, demonstrating that under certain 
conditions, Tel1 p does indeed playa critical role in the DDR. 
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As discussed in Chapter 1, recent data suggest novel roles for Tel1 in the DNA 
damage response. In addition, the transcriptional profiling of ATM-deficient cell lines failed 
to detect an A TM-dependent transcriptional defect (Chapter 2). Thus we hypothesize that 
genetic interactions suppress the loss of A TMITEL 1 in the DNA damage response. To 
comprehensively characterize the contexts by which Tel1p fits into the DDR, we 
performed genome-wide screens for TEL 1 genetic interactions that cause sensitivity to 
two different genotoxic agents, methylmethanesulfonate (MMS) and ionizing radiation 
(IR). From these screens, we have identified a diverse set of mutant backgrounds for 
which TEL 1 is required for survival upon exposure to DNA damage. We report that despite 
the diversity of teI1-LJ. interactions identified here, most share an additional common 
phenotype of an exacerbated telomere defect. 
Media and growth conditions 
YEPD and dropout media have been previously described (PAULOVICH et al. 1998). 
MMS and hydroxyurea (HU) were purchased from Sigma. YEPD and synthetic plates 
containing MMS were freshly prepared approximately 15 hours prior to use. 
Yeast strains and plasmids 
S. cerevisiae strains used in this study are listed in Table 14. Strain BY4741 and 
the haploid yeast knockout collection were purchased from Open Biosystems. Plasmid 
p4339 and strain Y7092 were gifts from Charles Boone and Brenda Andrews. Strain 
SLY60 was a gift from Sang Eun Lee; strain UCC3508 and plasmid pRS313-Y' were a 
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gift from Daniel Gottschling and plasmid pVL 1107 was gifted by Vicki Lundblad. All gene 
disruptions were achieved by homologous recombination at their chromosomal loci by 
standard polymerase-chain-reaction (PCR)-based methods (BRACHMANN et al. 1998). 
Briefly, a deletion cassette with a 0.5 kb region flanking the target ORF was amplified by 
PCR from the corresponding xxx::kanMX strain of the deletion array (Open Biosystems) 
and transformed into the target strain for gene knockout. The primers used in the gene 
disruptions are designed using 20-23 bp sequences that are 0.5 kb upstream and 
downstream of the target gene. A list of primer sequences for all knockouts used in this 
study is available upon request. 
teI1-11 double-deletion library construction and screening 
The Synthetic Gene Array (SGA) approach was used to construct a teI1-11 double-
deletion library following the protocol described in Tong & Boone (TONG and BOONE 2006). 
Library replication was performed using floating-pin manual replicators (VP Scientific). 
For the IR screen, the library was pin-replicated onto fresh YEPD plates and exposed to 
gamma irradiation using a Mark II cesium-137 irradiator (JL Shepherd & Associates) 
operated at varying dose rates. Plates were analyzed by manual inspection at 24 and 36 
hours following IR. For the MMS screen, the library was pin-replicated onto plates 
containing 0.01 % and 0.03% MMS, grown for two days at 30°C, and analyzed by visual 
inspection. 
MMS/IR spot and colony assays 
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For serial-dilution spot assays, log-phase cells were serially diluted in PBS and 
spotted onto YEPD or YEPD + MMS plates using a pin replicator. A subset of the plates 
was immediately irradiated using the conditions described above. Plates were incubated 
at 30°C and analyzed by visual inspection at 24 and 36 hours. 
For colony-based survival assays, three independent transformants were analyzed 
for each mutant, along with wild-type and teI1-11 controls. Log-phase cells (-5 x 107 cells) 
were sonicated and counted using a Beckman-Dickson Coulter counter. Cells were 
serially diluted in PBS and plated on YEPD or YEPD + MMS plates. For analyzing 
radiation sensitivity, cells were spread on YEPD plates and the plates were subsequently 
irradiated as described above. Viability was determined by plating serial dilutions of 
cultures onto YEPD and scoring the number of colony-forming units (CFU) after 3-4 days 
at 30°C. Viability was calculated as CFU/total cells. For experiments utilizing a low dose 
rate (0.9 Gy/minute), cells were irradiated in 5 ml liquid cultures over a 7.5 hour period 
prior to plating on YEPD to assess colony-based survival. In experiments in which a 
hydroxyurea pretreatment was used, cells were incubated in liquid YEPD media +/-
hydroxyurea (Sigma) at the indicated times. Following the incubation period, cells were 
washed twice with PBS, counted by Coulter counter, serially diluted and plated on YEPD 
or YEPD + MMS plates. 
Gross Chromosomal Rearrangement (GCR) and translocation assays 
For the measurement of GCR frequencies, log-phase cells grown at 30°C in YEPD 
were harvested, sonicated, and counted using a Coulter counter. 1 x 108 cells were 
resuspended in 20 ml YEPD and YEPD + 0.003% MMS and grown at 30°C overnight. At 
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15 hours, cells were washed in 5% Na2S03, sonicated, and counted using a Coulter 
counter. 1 x 109 cells were plated on C-Arg-Ser + Canavanine + 5-fluororotic acid (FOA) 
to measure GCR events, and serial dilutions were plated on YEPD to measure cell 
viability. GCR plates were incubated for 4-5 days at 30°C. Viability was calculated as 
CFU/total cells and MMS-induced GCR frequencies were normalized to GCR frequencies 
from untreated cells. 
The HO-inducible translocation assay was performed according to Lee et al (LEE 
et al. 2008). Briefly, log-phase cells were sonicated and cell number was determined 
using a Coulter counter (Beckman Dickson), and serial dilutions were plated on C-Ura 
dropout plates containing galactose to induce HO expression. Strain growth and 
translocations in the absence of HO-induced DSBs was measured on synthetic complete 
media and C-Ura plates containing glucose. 
Southern blotting 
Southern blotting for telomere lengths was carried out using a previously described 
DNA probe targeting telomeric Y' regions (SINGER et a/. 1998). DIG-labeled probe 
synthesis was carried out by PCR using the Roche DIG Probe Synthesis Kit following the 
manufacturer's instructions. Genomic DNA was prepared using a Yeastar genomic DNA 
kit (Zymo Research). Genomic DNA preparations were digested overnight with Xhol 
(Invitrogen) and separated on 1 % gels. Separated DNA molecules were transferred onto 
nylon membranes via blot sandwich overnight in 20X SSC buffer. DNA molecules were 
crosslinked onto the membrane using a UV crosslinker (Fisher Scientific) at 60 mJ/cm2 
and the membrane was incubated with the Y' telomeric DIG-labeled probe overnight. 
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Antibody detection of the DIG probe was performed using the DIG luminescent detection 
kit (Roche), and blots were imaged on a ChemiDoc XRS system (Bio-Rad). 
A synthetic genetic array (SGA) screen for interactions with tel1-il in response to 
MMS and IR. 
To better understand the extent of Tel1 p's role in the DDR we sought to 
characterize mutant backgrounds in which TEL 1 is required for survival in response to 
MMS and/or ionizing radiation. To achieve this, we constructed a genome-wide double-
deletion library by mating a MATa te/1-fJ. strain to the MATa haploid deletion library 
(WINZELER et at. 1999) using the Synthetic Genetic Array (SGA) procedure developed by 
Tong et a/ (TONG and BOONE 2006; TONG et at. 2001). The te/1-fJ. xxx-fJ. double-deletion 
library was screened for survival on YEPD plates containing either 0.01 % or 0.03% MMS. 
Plates were examined after 24 and 48 hours by visual inspection for double mutants that 
exhibited MMS sensitivity. Double mutant strains exhibiting sensitivity were subsequently 
spotted in 10-fold serial dilutions along with the parental single mutant strains on YEPD 
+ MMS to confirm the interaction. As an additional verification step, we re-made each 
single and double mutant by PCR-mediated transformation in a new BY4741 parental 
haploid strain. These new double-deletion mutants were then re-tested by serial-dilution 
spot assay on MMS plates and scored by visual inspection. Interactions passing this 
second criterion were then subjected to colony survival analyses to quantify the degree 
of interaction with te/1-fJ. on MMS plates. After validation, 13 gene deletions showed 
enhanced sensitivity to MMS when paired with te/1-fJ. (Figure 6). These genes include 
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multiple subunits of the 9-1-1 checkpoint clamp (RAD17, DDC1, -400 fold) as well as the 
9-1-1 clamp loader RAD24 (deletion of the third subunit mec3-L1 grows poorly in BY4741 
and was not able to be evaluated in the SGA screen), and members of the CCR4-NOT 
deadenylase complex (CCR4 and POP2; 6- to 130-fold). Additional interactions exhibiting 
greater than 10-fold increases in MMS sensitivity were the base excision repair 
endonuclease RAD27 (-30-fold) and a histone deacetylase (HDAC) subunit, HDA3 (-30-
fold). Additional genes exhibiting less than 10-fold interactions with teI1-L1 consisted of 
two nucleoporins (NUP60 and NUP133), the non-homologous-end-joining (NHEJ) repair 
factor YKUBO, a second HDAC subunit (SAP30) , the RAD26 ATPase, and a member of 
the Sm-like mRNA decay family (LSM7). We note that in the initial and confirmative 
screens, an additional teI1-L1 interaction with the uncharacterized FYV4 gene exhibited a 
growth defect with teI1-L1 as well as a >10-fold increase in MMS sensitivity. However, the 
FYV4 ORF is located -200 bp upstream of the transcription start site of the essential 
mediator subunit MED6. Transforming the fyv4-L1 teI1-L1 strain with a plasmid containing 
the MED6 gene and its promoter completely abolished the growth defect and MMS 
sensitivity of this strain (data not shown); leading us to conclude that the fyv4-L1 gene 
replacement exerts an off-target effect on the essential MED6 gene. Due to these 
complications the FYV41MED6 candidate was removed from further consideration in this 
study. 
As our MMS screen revealed a diverse set of interactions that cause enhanced 
MMS sensitivity with teI1-L1, we asked whether a different set of mutants would interact 
with teI1-L1 in response to a different DNA damaging agent, y-irradiation. To test for 
genetic interactions with teI1-L1 in ionizing radiation, the teI1-L1 xxx-L1 double-deletion 
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library was plated on YEPD and exposed to either 200 Gy or 400 Gy of ionizing radiation. 
In contrast to the MMS screen, only the 9-1-1 checkpoint genes rad17-iJ., ddc1-iJ. and 
rad24-iJ. exhibited interactions with teI1-iJ. in response to IR, and these interactions were 
minor «10-fold) in comparison to the 9-1-1-iJ. teI1-iJ. interactions in MMS (>100-fold) 
(Figure 7). To confirm that the teI1-iJ. xxx-iJ. interactions identified in the MMS sensitivity 
screen were indeed not also sensitive to IR, we tested each of the 13 MMS sensitive tel1-
iJ. xxx-iJ. strains for IR sensitivity. Consistent with the screen results, only the 9-1-1-iJ. tel1-
iJ. double mutants exhibited enhanced IR sensitivity (Figure 7). 
As MMS is often referred to as a 'radiomimetic' agent, the finding that many of the 
MMS interactions were not recapitulated using IR was unexpected. One possible 
explanation for this is that the 400 Gy of IR was delivered as a pulse over a short period 
of time (8 Gy/minute), while for MMS treatment cells were grown continuously in 0.03% 
MMS. (DNA damage phenotypes can differ significantly when the agent is delivered as a 
pulse or chronic treatment (MURAKAMI-SEKIMATA et al. 2010).) To test this hypothesis, 
three of the teI1-iJ. xxx-iJ. double mutants identified in our screen (ccr4-iJ. teI1-iJ., hda3-iJ. 
teI1-iJ. and rad17-iJ. teI1-iJ.) were examined for sensitivity to the same 400 Gy cumulative 
dose of IR (as in Figure 7), but this time delivered chronically over a period of 7.5 hours 
(0.9 Gy/minute). As seen in Figure 8, the totallR sensitivity for wild-type and single mutant 
strains was increased somewhat in the chronic exposure relative to the pulse of 400 Gy 
(Figure 7); however no additional (i.e. aside from 9-1-1) interactions with teI1-iJ. were 
observed, and the rad17-iJ. teI1-iJ. interaction was reduced. From this, we conclude that, 
unlike the MMS case, teI1-iJ. interactions in IR are limited to mutations in the 9-1-1 
pathway. 
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Loss of telomerase is associated with a progressive increase in MMS sensitivity 
Mammalian cells with shortened telomeres exhibit increased sensitivity to DNA 
damaging agents via an as-yet unknown mechanism (AGARWAL et al. 2008; DRISSI et al. 
2011; GONZALEZ-SUAREZ et al. 2003; GOYTISOLO et al. 2000; NAKAMURA et al. 2005; SOLER 
et al. 2009; WONG et al. 2000; Woo et al. 2012). Based on this precedent, we 
hypothesized that resistance to DNA damaging agents in yeast would also be tightly 
linked to telomere length, and that yeast cells would become more sensitive to DNA 
damage in a progressive manner as telomeres shorten. To evaluate this possibility, we 
employed a heterozygous diploid tlc1 strain, which upon sporulation into haploid progeny, 
exhibits progressive telomere shortening that leads to eventual replicative senescence 
(SINGER and GOTTSCHLING 1994). After inducing sporulation, we subcultured TLC1 and 
tlc1 haploid progeny over a series of days, and each day removed an aliquot of cells for 
testing of survival on YEPD or YEPD + MMS plates (Figure 9). In the absence of MMS, 
tlc1 strains exhibited progressive telomere shortening over the three day period, while 
telomere lengths in the TLC1 strains remained unchanged over the same period (Figure 
10). When tested for viability on plates containing either 0.01 % or 0.03% MMS, TLC1 
strains showed minimal MMS sensitivity that was unchanged over the course of the 
experiment (Figure 9). In contrast, the tlc1 mutant strains exhibited a progressive and 
dose-dependent increase in MMS sensitivity that was most pronounced by day 3 on 
0.03% MMS plates (survival rates in MMS were normalized to rates on YEPD alone to 
correct for MMS-independent loss of viability). As the half-life of telomerase RNA is a few 
hours (CHAPON et al. 1997) and the MMS sensitivity manifests after days, we conclude 
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that MMS sensitivity is telomere length-dependent in t1c1 cells, rather than due to TLC1 
loss alone. These results raised the interesting possibility that the DNA damage sensitivity 
exhibited by the identified te/1-lJ. xxx-lJ. interactions results from an exacerbation of the 
well-known telomere length defect caused by loss of TEL 1. 
Many of the teI1-11 MMS interactions exhibit shortened telomeres 
As cellular sensitivity to MMS increases progressively with telomere shortening 
(Figure 9), we hypothesized that some or all of the interactions identified in the te/1-lJ. 
screen exacerbate the te/1-mediated telomere length defect, and this may be a cause for 
DNA damage sensitivity in these cells. Thus we asked whether any of the te/1-lJ. xxx-lJ. 
double mutants exhibited telomere lengths that were significantly shorter than either 
corresponding single mutant. To answer this question, we isolated genomic DNA from 
single and double-mutants for each of the 13 te/1-lJ. xxx-lJ. interactions and analyzed Xho/ 
fragments by Southern blotting with a Y' subtelomeric probe (SINGER et al. 1998). As 
expected (GREENWELL et a/. 1995; LUSTIG and PETES 1986; MORROW et al. 1995), the te/1-
lJ. single mutant exhibited shorter telomere lengths relative to a wild-type strain (Figure 
11). Additionally, a number of the other single mutants exhibited shorter telomere lengths 
relative to the wild type, including yku80-lJ., rad27-lJ. and sap30-lJ., with the yku80-lJ. 
mutant being the only single-mutant exhibiting a shorter telomere length than te/1-lJ. 
(Figure 11). Notably, the 9-1-1 checkpointfactors ddc1-lJ. and rad17-lJ. strains were shown 
in a previous study to exhibit a minor telomere defect (LONGHESE et al. 2000). However, 
we did not observe discernible shortening of these mutants relative to the wild type (Figure 
11 and 12); this may reflect differences in the strain background used between these 
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studies. Notably, the 9-1-1-fJ. teI1-fJ. double mutants (rad24-fJ. teI1-fJ., rad17-fJ. tel1 and 
ddc1-fJ. teI1-fJ.) exhibited very short telomeres relative to teI1-fJ., and a second class 
consisting of sap30-fJ. teI1-fJ., ccr4-fJ. teI1-fJ., pop2-fJ. teI1-fJ., hda3-fJ. teI1-fJ., nup133-fJ. tel1-
fJ., nup60-11 tel1-fJ., rad27-fJ. teI1-fJ. and ykuBO-fJ. teI1-fJ. also exhibited shorter telomeres 
relative to teI1-fJ.. The rad26-fJ. te11-11 and Ism7-fJ. teI1-fJ. double mutants exhibited 
telomere lengths that were identical to teI1-fJ.. Our finding that eleven of the thirteen tel1-
fJ. xxx-fJ. interactions exhibited decreased telomere lengths relative to teI1-fJ. is 
unexpected, since many of identified genes play no known role in telomere metabolism. 
To exclude the possibility that the teI1-fJ. xxx-fJ. short telomere phenotype was not merely 
an artifact due to a previously-characterized phenotypic lag for tel1 telomeres (-150 
generations (LUSTIG and PETES 1986)), we examined telomere lengths for a selection of 
single- and double-mutants over additional sub-culturing for a period of five days. During 
the repeated subculturing, we did not observe any further changes in telomere length by 
Southern blot (Figure 12). From these data, we conclude that the majority of teI1-fJ. 
interactions identified in the MMS sensitivity screen also confer shorter telomeres, 
suggesting a possible connection between the two phenotypes. 
Artificial elongation of telomeres in te/1-11 9-1-1-11 mutants partially suppresses 
MMS sensitivity 
As telomere shortening was shown to be causative for MMS sensitivity in the t1c1 
case (Figure 9), we next hypothesized that the exacerbated telomere defect exhibited by 
the majority of teI1-fJ. xxx-l1 strains (Figure 11) may be causative for enhanced MMS 
sensitivity. Thus, reversal of the telomere length defect would also reduce the MMS 
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sensitivity of these mutants. To test this, we transformed each of the teI1-11 xxx-11 single-
and double-mutants with a plasmid expressing a fusion of the Cdc13 capping protein to 
the Est2 subunit of telomerase (EVANS and LUNDBLAD 1999). This fusion has been 
previously shown to alleviate the short telomere phenotype in a tel1 mutant (TSUKAMOTO 
et a/. 2001). A panel of teI1-11 xxx-11 mutant strains with and without the CDC13-EST2 
plasmid was screened for sensitivity by spotting cells on MMS plates (Figure 13). Of the 
tested teI1-11 xxx-11 interactions, the rad24-11 teI1-11 strain exhibited a visible increase in 
survival on MMS plates when transformed with the CDC13-EST2 fusion plasmid (and not 
the vector). None of the other teI1-11 xxx-11 interactions exhibited any change in MMS 
sensitivity upon transformation with CDC13-EST2. We confirmed the suppression of 
MMS sensitivity in rad24-11 teI1-11 as well as a second 9-1-1 component (rad17-11 teI1-1J.) 
by a quantitative colony forming assay (Figure 14), and again the fusion plasmid 
conferred discernible (but not total) resistance to MMS (11-fold for rad24-11 teI1-11 and 4-
fold for rad17-11 teI1-11 versus the vector). Telomeres in these strains were significantly 
elongated to wild-type levels by addition of the CDC13-EST2 fusion and were hyper-
elongated in wild-type and teI1-11 strains (Figure 14). (CDC13-EST2 was able to elongate 
telomeres to an identical degree in other non-9-1-1-related teI1-11 xxx-11 interactions (not 
shown) despite having no effect on MMS resistance.) While expression of CDC13-EST2 
suppresses the strong (>100-fold) MMS sensitivity in 9-1-1-11 teI1-11 interactions by -10-
fold (Figure 14), the fact that this suppression is not total, nor does CDC13-EST2 
expression affect the MMS sensitivity of the other teI1-11 xxx-11 interactions suggests that 
there are additional telomere-length-independent defects that contribute to the MMS 
sensitivity of teI1-11 xxx-11 interactions. 
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te/1-iJ. xxx-iJ. interactions do not affect the frequency of NHEJ-mediated 
translocations 
Lee and colleagues previously described an 11-fold increase in the frequency of 
DSB-induced NHEJ-mediated translocations for a teI1-11 mutant, reflecting a role for TEL 1 
in preventing deleterious chromosomal fusions through an as-yet undefined mechanism 
(LEE et al. 2008). That a teI1-11 strain is not sensitive to DNA damaging agents despite 
this defect suggests that the occurrence of these events even in the presence of DNA 
damaging agents is a rarity. Thus, one possibility is that the teI1-11 xxx-l1 interactions 
identified here may increase cellular dependence on TEL 1 to prevent deleterious 
chromosomal fusions. We tested this possibility by determining whether the teI1-11 xxx-l1 
double mutants experience enhanced frequencies (compared to tel1) of chromosomal 
translocations. We cloned each of the 13 single mutants and teI1-11 xxx-l1 double mutants 
into a strain background harboring the translocation assay construct (LEE et al. 2008) that 
employs two GAL-inducible HO cuts on chromosomes V and VII, where each breakpoint 
contains a nonfunctional fragment of the URA3 gene. Translocations are measured by 
the reconstitution of a functional URA3 allele, which is dependent on Ku70/80-mediated 
NHEJ (LEE et al. 2008). We measured the frequency of translocations after the induction 
of GAL-HO for the panel of teI1-11 xxx-l1 interaction strains (Figure 15). While we were 
able to reproduce the Ku-dependent increase in Ura+ translocations for teI1-11 , none of 
the other double mutants exhibited frequencies that differed from teI1-11. From this we 
conclude that an increased frequency of DSB-induced chromosomal translocations is 
unlikely to be the cause of the MMS sensitivity exhibited by teI1-11 xxx-l1 interactions. This 
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is supported by the fact that the teI1-LJ. xxx-LJ. MMS interactions were also largely 
insensitive to IR (Figure 7), which directly induces DSBs (whether or not MMS produces 
DSBs is a current source of controversy (LUNDIN et al. 2005)). 
Gross chromosomal rearrangements in teI1-/j xxx-/j strains 
Kolodner and colleagues have previously shown that one double mutant identified 
in this screen (rad24 tel1) causes an increased frequency of spontaneous chromosome 
breakage and rearrangement involving the left arm of chromosome V (the gross 
chromosomal arrangement (GCR) assay) (MVUNG and KOLODNER 2002). As MMS has 
also been shown to induce higher GCR frequencies (MVUNG and KOLODNER 2003; 
STELLWAGEN et al. 2003), we asked whether the MMS sensitivity exhibited by the teI1-LJ. 
xxx-LJ. double mutants may reflect an increased frequency of MMS-induced genome 
rearrangements. To do this, we grew single- and double-mutant strains in the presence 
of 0.003% MMS for 15 hours to induce GCR events, which were detected by selecting for 
the loss of two nearby markers (CAN1 and URA3) on the left arm of chromosome V, as 
previously described (CHEN and KOLODNER 1999). The 0.003% MMS exposure resulted 
in a -10-fold induction of GCR events for wild-type cells. For the teI1-LJ. xxx-LJ. double 
mutants, members of the 9-1-1 complex showed a -300 fold induction of MMS-induced 
GCR events when combined with teI1-LJ. (Figure 16). The rad27-LJ. teI1-LJ. mutant and 
nup60-LJ. teI1-LJ. each showed a minor -5-fold increase in MMS-induced GCR. None of 
the other double mutants exhibited an increased GCR frequency (Figure 16a). From 
these data, we conclude that a subset of teI1-LJ. xxx-LJ. interactions (rad17-LJ. teI1-LJ., ddc1-
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11 te/1-11, rad24-11 te/1-11, rad27-11 te/1-11 and nup60-11 te/1-11) exhibit increased genome 
instability as measured by the GCR assay. 
As restoration of telomere lengths through addition of the CDC13-EST2 fusion 
plasmid restored a proportion of MMS resistance to the 9-1-1-11 te/1-11 mutant strains, we 
asked whether the CDC 13-ES T2 fusion would also suppress the increased MMS-induced 
GCR frequency of a 9-1-1-11 te/1-11 mutant as well. We tested a rad17-11 te/1-11 mutant 
along with the corresponding single mutants for the induction of GCR events with or 
without the fusion construct. As can be seen in Figure 16b, the rad17-11 te/1-11 double-
mutant strain harboring the fusion plasmid had a reduced GCR frequency relative to the 
same strain carrying an empty vector. Consistent with a partial reduction in MMS 
sensitivity, the CDC13-EST2 fusion did not completely abolish MMS-induced gross 
chromosomal rearrangements in the rad17-11 te/1-11 strain. From these data, we conclude 
that a proportion of the MMS sensitivity exhibited by 9-1-1-11 te/1-11 strains is due to MMS-
induced genomic instability that is caused by telomere shortening. However, much of the 
increased GCR in 9-1-1-11 te/1-11 is unexplained by telomere length effects; thus additional 
mechanisms (i.e. aside from altered telomere length) contribute to the sensitivity of te/1-
11 xxx-11 interactions. 
A teI1-11 strain is rendered sensitive to MMS by pre-depletion of nucleotide pools 
Prior studies have implicated both the 9-1-1 complex and CCR4-NOT complex as 
key regulators of ribonucleotide reductase, and mutants in these pathways exhibit 
depleted nucleotide pools and are sensitive to replication stress (MULDER et a/. 2005; 
TRAVEN et a/. 2005; WESTMORELAND et a/. 2004; WOOLSTENCROFT et a/. 2006; ZHAO et a/. 
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2001). Moreover, a ccr4-fJ. te/1-fJ. strain has been previously shown to exhibit enhanced 
sensitivity to the ribonucleotide reductase inhibitor hydroxyurea (WOOLSTENCROFT et a/. 
2006). Thus we hypothesized that a decrease in dNTP pools in 9-1-1-fJ. te/1-fJ. and ccr4-
fJ. / pop2-11 te/1-fJ. may contribute to the MMS sensitivity exhibited by these strains. From 
this, we predicted that depletion of nucleotide pools (e.g. by pretreating cells with 
hydroxyurea) in te/1-fJ. cells should phenocopy deletion of CCR4 in a te/1-11 background, 
thus sensitizing te/1-fJ. cells to MMS. To test this prediction, wild-type and te/1-fJ. cells 
were cultured in rich medium with 0, 50 or 150 mM HU for a period of four hours, after 
which the HU was removed, and cells were plated onto MMS plates to assess viability. 
As expected, the MMS sensitivity of a wild-type strain does not change, regardless of 
whether the cells were pretreated with HU (Figure 17). In contrast, while a te/1-fJ. strain is 
insensitive to the HU pretreatment alone, when HU pretreatment is followed by plating on 
MMS plates, te/1-fJ. cells exhibit enhanced MMS sensitivity in a dose-dependent manner, 
with the greatest MMS sensitivity observed in 150 mM HU (Figure 17). From this we 
conclude that depletion of nucleotide pools renders te/1-fJ. sensitive to the DNA damaging 
agent MMS, consistent with a model in which increased replication stress contributes to 
the MMS sensitivity exhibited by the 9-1-1-fJ. te/1-fJ. and ccr4-fJ. te/1-fJ. / pop2-fJ. te/1-fJ. 
mutants (and possibly other te/1-11 xxx-fJ. double mutants isolated in the screen; see 
Discussion). 
Categorizing the te/1-11 interactions 
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While a tel1-fJ mutant exhibits interactions with a diverse set of 13 mutants, we 
found that these interactions fell into three phenotypic classes based upon our follow-up 
characterizations (Table 15). The first class is comprised of mutants in the 9-1-1 complex 
(rad17-fJ and ddc1-fJ) and the 9-1-1 clamp loader (rad24-fJ); these tel1-fJ interactions 
conferred a rather large (>100-fold) increase in MMS sensitivity (Figure 6), cross-
sensitivity to IR (Figure 7 and 8), a pronounced telomere defect (Figure 11) and a 
synergistic increase in GCR events (Figure 16). For this class, the DNA damage 
sensitivity and the increase in GCR frequencies were partially suppressed by elongating 
telomeres using the COC13-EST2 fusion construct (Figure 14 & 16b). The second class 
of interactions comprises ccr4-fJ, pop2-fJ, sap30-fJ, hda3-fJ, yku80-fJ, rad27-fJ, nup133-
fJ and nup60-fJ (Table 15); these exhibited a somewhat milder interaction with tel1-fJ in 
MMS, no cross-sensitive interactions to IR, but exhibited a discernible telomere length 
defect with tel1-fJ (Figure 11). The third class of mutants, rad26-fJ and Ism7-fJ showed 
similar characteristics to class 2, but did not exhibit any discernible telomere length defect 
(Figure 11). There is likely some overlap between these classes in the mechanism 
causing their interactions with teI1-fJ, discussed below. 
A replication defect underlies sensitivity to MMS in multiple classes of teI1-i1 
interactions 
While the tel1-fJ interactions comprising classes 1 and 2 (Table 15) exhibit 
shortened telomeres relative to the corresponding single mutants, only in the class 1 case 
is MMS sensitivity suppressed by telomere elongation (Figure 14), and even in this class 
of double mutants the suppression is modest. While it is formally possible that telomere 
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elongation due to the expression of the CDC13-EST2 fusion creates a structure that is 
somehow physiologically different from a natural telomere and thus is not a good 
substitute, a more straightforward model is that only a minor proportion of MMS sensitivity 
is directly caused by telomere shortening in class 1 mutants, while the majority of MMS 
sensitivity in these and other te/1-fJ. xxx-fJ. interactions reflects an underlying replication 
defect that manifests a dual-pronged effect on telomere metabolism and MMS resistance. 
Our data (and other studies) support a model in which increased replication stress, 
combined with a te/1-fJ.-mediated defect in replication fork stability causes both MMS 
sensitivity and telomere shortening in te/1-fJ. xxx-fJ. interactions. First, aside from a modest 
effect in the class 1 mutants, none of the identified in te/1-fJ. xxx-fJ. interactions exhibit 
cross-sensitivity to ionizing radiation, regardless of whether the IR was administered as 
a pulse (Figure 7) or chronic treatment (Figure 8). Unlike MMS treatment, IR does not 
induce detectable replication fork stalling (MERRICK et al. 2004), so while there is a minor 
IR interaction in te/1-fJ. 9-1-1-fJ. cells (Figure 7) (likely through an additive defect in 
Mec1fTel1 DSB sensing), replication fork stalling/collapse is the likely major lethal lesion 
in te/1-fJ. xxx-fJ. interactions. Additionally, recent studies have uncovered a TEL 1-
dependent role in the preservation of fork stability through the prevention of fork reversion 
and degradation into abnormal cruciform structures (DOKSANI et al. 2009). Consistent with 
this, Kaochar et al. showed that te/1-fJ. exhibits an increased frequency of dicentric 
chromosomes due to the fusion of inverted repeats likely due to fork reversion (KAOCHAR 
et al. 2010). As the reason why te/1-fJ. cells exhibit short telomeres is poorly understood, 
it is formally possible that a failure to preserve fork stability in telomeric regions in te/1-fJ. 
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cells is causative for the short telomere phenotype (telomeres are enriched for replication 
pause sites such as G-quadruplex structures (BOCHMAN et a/. 2012; IVESSA et a/. 2002)). 
Many of the te/1-11 interactions identified in the MMS screen fit a model for 
increased replication stress. Members of class 1 (9-1-1 components) (Table 15) are 
required for the MEC1-dependent degradation of the ribonucleotide reductase inhibitor 
Sml1 following MMS treatment (CHABES et al. 2003; ZHAO et al. 2001); the resultant 
increase in dNTP production following this process is thought to facilitate DNA synthesis 
at stalled forks to prevent fork collapse (FASULLO et al. 2010). In addition, members of 
class 2 (CCR4 and POP2, members of the CCR4-NOT deadenylation complex) are 
known regulators of ribonucleotide reductase, and mutants in ccr4-11 and pop2-11 are 
sensitive to replication inhibitors such as hydroxyurea (MULDER et al. 2005; TRAVEN et al. 
2005; WESTMORELAND et al. 2004; WOOLSTENCROFT et a/. 2006). As telomere shortening 
has recently been shown to occur upon dNTP depletion (GUPTA et al. 2013), it is likely 
that the short telomeres in CCR4-NOT and 9-1-1 mutants are at least partially due to this 
mechanism. Consistent with a model for increased replication stress in te/1-11 xxx-l1 cells, 
depleting nucleotide pools by pretreatment with hydroxyurea (effectively phenocopying 
the loss of 9-1-1 or CCR4IPOP2) sensitizes te/1-11 cells to MMS in a dose-dependent 
manner, whereas a wild-type strain is unaffected by the HU pretreatment (Figure 17). 
Other mutants comprising class 2 are also linked to preventing replication stress 
via counteracting fork regression (RAD27 (KANG et a/. 2010)) or stabilizing sites of active 
transcription (NUP60INUP133 (BERMEJO et a/. 2011; PALANCADE et al. 2007)). 
Additionally, the mutants comprising class 3 (Table 15) are linked to increased replication 
stress due to defects in histone regulation (LSM7 (HERRERO and MORENO 2011; TKACH et 
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al. 2012)) or through defective targeting of transcription-coupled repair (RAD26 (KAPITZKY 
et al. 2010; MALIK et al. 2010)). 
Progressive telomere shortening is a cause for MMS sensitivity 
Recently, numerous studies have described a connection between short telomeres 
and enhanced sensitivity to DNA damaging agents across a variety of organisms (DRISSI 
et al. 2011; LIN et aJ. 2009; SOLER et al. 2009; WONG et al. 2000); the reason for this 
relationship is poorly understood. Here, we show that in yeast, cellular sensitivity to MMS 
progressively increases as telomeres shorten (Figure 9), suggesting that the progressive 
loss of telomere protection renders cells sensitive to MMS. In concordance with this, a 
proportion of MMS sensitivity and genome instability can be suppressed in 9-1-1-11 tel1-
11 mutants by alleviating the short telomere phenotype in these cells (Figures 14). 
There are multiple possible mechanisms for how short telomeres cause MMS 
sensitivity. Loss of telomeric protection can render telomeres targets for the DDR and the 
loss of telomerase activity is associated with a gradual increase in constitutive Rad53 
phosphorylation (GRANDIN et al. 2005); accordingly in telomerase-deficient cells 
telomeres are enriched for DDR proteins while non-telomeric DSBs exhibit reduced 
binding of DDR factors (LIN et al. 2009). Thus, the recruitment of DDR factors to short 
telomeres may interfere with the ability of the cell to cope with MMS-induced stress 
elsewhere in the genome. Alternatively, de-protected telomeres themselves may be 
problematic in the presence of MMS due to the potential for lethal chromosomal fusions 
with DSBs resulting from MMS-induced collapsed forks. Supporting this, a subset of GCR 
events can be suppressed by elongating telomeres in 9-1-1-11 teI1-11 (Figure 16), and a 
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previous study has shown that a 9-1-1-iJ. te/1-iJ. double-mutant exhibits an increased 
frequency of spontaneous telomere-telomere fusions that can also be suppressed by 
elongating telomeres (MIECZKOWSKI et al. 2003). 
For the other identified interactions, (Class 2, Table 15) despite a lack of MMS 
suppression by CDC13-EST2, the telomere defect in these cells may still be a cause for 
MMS sensitivity. For example, an increase in ssDNA at telomeres would create a 
structure that is more susceptible to MMS-induced lesions (fork-blocking lesions occur 
predominantly in ssDNA in MMS (SHRIVASTAV et al. 2010)). Accordingly, a rad27 mutant 
is associated with abnormally large regions of ssDNA in telomeres (PARENTEAU and 
WELLINGER 1999). As DNA damage in telomeres has recently been shown to be uniquely 
irreparable (FUMAGALLI et al. 2012), it is likely that telomeres exhibiting abnormal 
structures are both more susceptible to MMS-induced damage and less able to survive 
it. 
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MA Ta his3lJ. 1 leu2lJ.0 met15lJ.0 ura3lJ.0 
MATa can1/':,.::STE2pr-Sp_his5Iyp1/':,. his3/':,.1leu2deltaO ura3/':,.0 
met15/':,.0 
MA TalMA Ta ura3-52Iura3-52 lys2-B011'ys2-B01 ade2-
1 011ade2-1 01 his3-lJ.200Ihis3-lJ.200 trp 1-lJ. 1ITRP1 leu2-lJ. 1/1eu2-
lJ. 1 adh4::URA3-TEUadh4::URA3-TEL DIA5-1IDIA5-1 
ppr1::HIS3Ippr1::L YS2 TLC1Itlc1:LEU2 
MAT/':,.3':intron:ura3/':,.5' ho/':,. hml/':,.:ADE1 hmr/':,.:ADE1 ade1-100 
leu2-3, 112 lys5 trp1:hisG ura3/':,.3':intron:HOcs ade3:GALHO 
MATa can1/':,.::STE2pr-Sp_his5Iyp1/':,. his3M leu2deltaO ura3/':,.0 
met1MO teI1::NATMX 
MA Ta his3lJ. 1 leu2lJ.0 met15lJ.0 ura3lJ.0 hxt3::URA3 
MAT/':,.3':intron:ura3/':,.5' ho/':,. hml/':,.:ADE1 hmr/':,.:ADE1 ade1-100 
leu2-3, 1121ys5 trp1:hisG ura3/':,.3':intron:HOcs ade3:GALHO 
teI1:NATMX 
MA Ta his3lJ. 1 leu2lJ.0 met15lJ.0 ura3lJ.0 hxt3::URA3 
teI1::NATMX 
MA Ta his3lJ. 1 leu2lJ.0 met15lJ.0 ura3lJ.0 hxt3::URA3 
pop2::KANMX 
MA Ta his3lJ. 1 leu2lJ.0 met15lJ.0 ura3lJ.0 hxt3::URA3 
sap30::KANMX 
MAT/':,.3':intron:ura3/':,.5' ho/':,. hml/':,.:ADE1 hmr/':,.:ADE1 ade1-100 
leu2-3, 1121ys5 trp1:hisG ura3/':,.3':intron:HOcs ade3:GALHO 
teI1::NATMX rad17::KANMX 
MAT/':,.3':intron:ura3/':,.5' ho/':,. hml/':,.:ADE1 hmr/':,.:ADE1 ade1-100 
leu2-3, 1121ys5 trp1:hisG ura3/':,.3':intron:HOcs ade3:GALHO 
teI1::NATMX ddc1::KANMX 
MAT/':,.3':intron:ura3/':,.5' ho/':,. hml/':,.:ADE1 hmr/':,.:ADE1 ade1-100 
leu2-3, 1121ys5 trp1:hisG ura3/':,.3':intron:HOcs ade3:GALHO 
teI1::NATMX nup60::KANMX 
MAT/':,.3':intron:ura3/':,.5' ho/':,. hml/':,.:ADE1 hmr/':,.:ADE1 ade1-100 
leu2-3, 1121ys5 trp1:hisG ura3/':,.3':intron:HOcs ade3:GALHO 
teI1::NATMX nup133::KANMX 
MA T/':,.3':intron:ura3/':,.5' ho/':,. hml/':,.:ADE1 hmr/':,.:ADE1 ade1-100 
leu2-3, 1121ys5 trp1:hisG ura3/':,.3':intron:HOcs ade3:GALHO 
teI1::NATMX Ism7::KANMX 
MAT/':,.3':intron:ura3/':,.5' ho/':,. hml/':,.:ADE1 hmr/':,.:ADE1 ade1-100 
leu2-3, 1121ys5 trp1:hisG ura3/':,.3':intron:HOcs ade3:GALHO 
teI1::NATMX sap30::KANMX 
MAT/':,.3':intron:ura3/':,.5' ho/':,. hml/':,.:ADE1 hmr/':,.:ADE1 ade1-100 
leu2-3, 1121ys5 trp1:hisG ura3/':,.3':intron:HOcs ade3:GALHO 
tel 1 ::NA TMX hda3::KANMX 
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yBP1553-55 MA Ta his3IJ 1 leu2IJO met15IJO ura3IJO hxt3::URA3 This study 
nup60::KANMX 
yBP1558-60 MA Ta his3IJ 1 leu2IJO met15IJO ura3IJO hxt3::URA3 This study 
tel 1 ::NA TMX rad17::KANMX 
yBP1564-66 MA Ta his3IJ 1 leu2IJO met15IJO ura3IJO hxt3::URA3 This study 
tel1 ::NA TMX nup60::KANMX 
yBP1576-78 MA Ta his3IJ 1 leu2IJO met15IJO ura3IJO hxt3::URA3 This study 
tel1 ::NA TMX sap30::KANMX 
yBP1585-87 MA Ta his3IJ 1 leu2IJO met15IJO ura3IJO hxt3::URA3 This study 
tel1 ::NA TMX hda3::KANMX 
yBP1608-10 MA Ta his3IJ 1 leu2IJO met15IJO ura3IJO hxt3::URA3 This study 
nup133::KANMX 
yBP1611-13 MA Ta his3IJ 1 leu2IJO met15IJO ura3IJO hxt3::URA3 This study 
teI1::NATMX nup133::KANMX 
yBP1622-23 MA T!13':intron:ura3t:.5' hot:. hmlt:.:ADE1 hmrt:.:ADE1 ade1-100 This study 
leu2-3, 1121ys5 trp1:hisG ura3t:.3':intron:HOcs ade3:GALHO 
teI1::NATMX pop2::KANMX 
yBP1630-32 MA Ta his3IJ 1 leu2IJO met15IJO ura3IJO hxt3::URA3 This study 
rad26::KANMX 
yBP1633-35 MA Ta his3IJ 1 leu2IJO met15IJO ura3IJO hxt3::URA3 This study 
teI1::NA TMX rad26::KANMX 
yBP1636-38 MAT!13':intron:ura3t:.5' hot:. hmlt:.:ADE1 hmrt:.:ADE1 ade1-100 This study 
leu2-3, 112 lys5 trp1 :hisG ura3t:.3':intron:HOcs ade3:GALHO 
teI1::NATMX rad26::KANMX 
yBP1669-71 MA Ta his3IJ 1 leu2IJO met15IJO ura3IJO hxt3::URA3 This study 
ccr4::KANMX 
yBP1672-74 MATa his3IJ 1 leu2IJO met15IJO ura3IJO hxt3::URA3 This study 
teI1::NATMX ccr4::KANMX 
yBP1681-83 MA Ta his3IJ 1 leu2IJO met15IJO ura3IJO hxt3::URA3 This study 
Ism7::KANMX 
yBP1684-86 MATa his3IJ 1 leu2IJO met15IJO ura3IJO hxt3::URA3 This study 
teI1::NATMX Ism7::KANMX 
yBP1714-16 MA Ta his3IJ 1 leu2IJO met15IJO ura3IJO hxt3::URA3 This study 
hda3::KANMX 
yBP1717-19 MA Ta his3IJ 1 leu2IJO met15IJO ura3IJO hxt3::URA3 This study 
ddc1::KANMX 
yBP1720-22 MA Ta his3IJ 1 leu2IJO met15IJO ura3IJO hxt3::URA3 This study 
teI1::NATMX ddc1::KANMX 
yBP1738-40 MA Ta his3IJ 1 leu2IJO met15IJO ura3IJO hxt3::URA3 This study 
tel1 ::NA TMX pop2::KANMX 
yBP1787-89 MA Ta his3IJ 1 leu2IJO met15IJO ura3IJO hxt3::URA3 This study 
fyv4::KANMX 
yBP1790-92 MA Ta his3IJ 1 leu2IJO met15IJO ura3IJO hxt3::URA3 This study 
tel1 ::NATMX fyv4::KANMX 
yBP1793-95 MA Ta his3IJ 1 leu2IJO met15IJO ura3IJO hxt3::URA3 This study 
yku8O::KANMX 
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yBP1796-98 MATa his3lJ.1 leu2lJ.O met15lJ.O ura3lJ.O hxt3::URA3 This study 
teI1::NATMX yku80::KANMX 
yBP1799-1801 MATa his3lJ.1 leu2lJ.O met15lJ.O ura3lJ.O hxt3::URA3 This study 
rad27::KANMX 
yBP1802-04 MA Ta his3lJ.1 leu2lJ.O met15lJ.O ura3lJ.O hxt3::URA3 This study 
tel 1 ::NA TMX rad27::KANMX 
yBP1805-07 MA Ta his3lJ.1 leu2lJ.O met15lJ.O ura3lJ.O hxt3::URA3 This study 
rad24::KANMX 
yBP1808-10 MATa his3lJ.1 leu2lJ.O met15lJ.O ura3lJ.O hxt3::URA3 This study 
teI1::NATMX rad24::KANMX 
yBP1838-40 MA Tt:,.3':intron:ura3/',.5' ho/',. hm//',.:ADE1 hmr/',.:ADE1 ade1-100 This study 
leu2-3, 112 lys5 trp1:hisG ura3/',.3':intron:HOcs ade3:GALHO 
teI1::NATMX ccr4::KANMX 
yBP1841-43 MAT/',.3':intron:ura3/',.5' ho/',. hm//',.:ADE1 hmr/',.:ADE1 ade1-100 This study 
leu2-3, 112 lys5 trp1 :hisG ura3/',.3':intron:HOcs ade3:GALHO 
yku80::KANMX 
yBP1844-46 MA Tt:,.3':intron:ura3/',.5' ho/',. hml/',.:ADE1 hmr/',.:ADE1 ade1-100 This study 
leu2-3, 112 lys5 trp1:hisG ura3/',.3':intron:HOcs ade3:GALHO 
teI1::NATMX yku80::KANMX 
yBP1847-49 MAT/',.3':intron:ura3/',.5' ho/',. hm//',.:ADE1 hmr/',.:ADE1 ade1-100 This study 
leu2-3, 1121ys5 trp1:hisG ura3/',.3':intron:HOcs ade3:GALHO 
rad27::KANMX 
yBP1850-52 MA Tt:,.3':intron:ura3/',.5' ho/',. hm//',.:ADE1 hmr/',.:ADE1 ade1-100 This study 
leu2-3, 1121ys5 trp1:hisG ura3/',.3':intron:HOcs ade3:GALHO 
teI1::NATMX rad27::KANMX 
yBP1859-61 MATt:,.3':intron:ura3/',.5' ho/',. hml/',.:ADE1 hmr/',.:ADE1 ade1-100 This study 
leu2-3, 1121ys5 trp1:hisG ura3/',.3':intron:HOcs ade3:GALHO 
rad24::KANMX 
yBP1862-64 MA Tt:,.3':intron:ura3/',.5' ho/',. hm//',.:ADE1 hmr/',.:ADE1 ade1-100 This study 
leu2-3, 1121ys5 trp1:hisG ura3/',.3':intron:HOcs ade3:GALHO 
teI1::NATMX rad24::KANMX 

















TABLE 15. TABULATION OF PHENOTYPES UNCOVERED IN THIS STUDY. 














For each of the tell-,1 xxx-,1 genetic interactions identified in the MMS screen a '+' indicates whether a 
double mutant exhibited a positive result in each of the assays tested (e.g. increased GCR frequency, 
shorter telomere etc.; a '++' indicates a more severe phenotype and '+/-' indicates partial suppression). 













$ 11 __ .__-
~ I 
~ 0.1 r. I '-III-----~~-- - -- ---~ r- - - -- -
~ 
~ '#. 0.01 l- - . -.__--. -- --. - .I-"±:-
~ ~ I 
-- --~ - - -
---
* 
r- - ---- r- - I-- r-
* 
___ -II-II--ll---~ r-- - -
- -
0>0 0 0.001 .L --- '--. _ _ --11 ________ - 11--:: '-- - -- '- - '--
-l 0.0001 ~-r- ---"-,,- '"-r-I-,-J--.---l --~._.---'_r_.--- ,--'_,_'"- "--, __ -.--,-__ '_.-'~-__ '-r-'--.-..--~.__-'-.-I'__,,----.---.-c...--
FIGURE 6. QUANTITATIVE SURVIVAL ANALYSIS FOR TELl INTERACTIONS IN MMS VIA COLONY-FORMING ASSAY. 
Quantitative survival analysis in MMS. Log-phase cultures for three independent transformants of 
each single and double mutant were serially diluted in PBS and spread on YEPD or YEPD + 0.03% 
MMS plates (asterisks indicate that screening was done in 0.015% MMS due to extreme MMS 
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FIGURE 7. QUANTITATIVE SURVIVAL ANALYSIS IN IR. 
Log-phase cultures for three independent transformants of each single and double mutant were 
serially diluted in PBS and spread on YEPD plates and irradiated at 400 Gy at 8 Gy/min. Viable cells 
were determined by the number of colony-forming units (CFU) after 3 days at 30QC. Arrows indicate 
interactions identified in the genome-wide screen. Error bars represent the standard deviation of 

























FIGURE 8. QUANTITATIVE SURVIVAL ANALYSIS USING CONTINUOUS LOW DOSE-RATE IR. 
Log-phase cultures for two independent transformants of each single and double mutant were 
diluted into YEPD in 15 ml tubes and irradiated with 400 Gy delivered at a continuous dose rate of 
0.9 Gy/minute over 7.5 hours. Following delivery of IR, cells were counted, serially diluted and 
plated for colony survival analysis. Error bars show the range of values for two independent 
transformants. 
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FIGURE 9. TELOMERASE-NULL CELLS EXHIBIT A PROGRESSIVE INCREASE IN MMS SENSITIVITY. 
TLCl and tIel haploid spores from freshly dissected tetrads were subcultured in YEPD over multiple 
days. Each day, an aliquot was removed and assayed for MMS sensitivity by colony forming assay. 















FIGURE 10. SOUTHERN BLOT FOR TELOMERE LENGTHS OF ne1 AND ne1 HAPLOID SPORES. 
Genomic DNA from spores with or without a functional TLCl gene was isolated over three 
consecutive days of subculturing. DNA were separated by electrophoresis, blotted onto 
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FIGURE 11. TELOMERE LENGTHS FOR TEL1-d MMS-SENSITIVE INTERACTIONS. 
For each strain, Xhol-digested DNA was analyzed by Southern blot using 
a probe complementary to the Y' subtelomere. Each xxx-L1 mutant is 
listed to the left of each corresponding blot, and duplicates representing 
independent transformants for each strain are loaded side-by-side 
(duplicates are indicated by the brackets above). DNA ladders (in kb) are 
indicated in the far left or right lane of each blot. 
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FIGURE 12. REPEATED SUBCULTURING DOES NOT ALTER TELOMERE LENGTHS. 
Wildtype, tell-/j, rad17-/j and rad17-/j tell-/j cultures were diluted into fresh YEPO media and grown 
overnight. Genomic DNA was harvested the following day and a portion of the cells was diluted in 
to fresh medium and cultured overnight. The process was repeated over a period of five days (01-
05). Xhol-digested DNA was analyzed by gel electrophoresis and Southern blotting with a probe 
recognizing subtelomeric Y' sequence. Molecular weight markers are indicated on the left (kb). 
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wild-type + vector 
wt + CDC13-EST2 
lel1 + vector 
lel1 + CDC13-EST2 
rad24 lel1 + vector 
rad241al1 + CDC13-EST2 
sap30lal1 + vector 
sap30lal1 + CDC13-EST2 
nup60lal1 + vector 
nup60lal1 + CDC13-EST2 
Ism71el1 + vector 
Ism71el1 + CDC13-EST2 
pop21al1 + vector 
pop2lal1 + CDC13-EST2 
ccr41al1 + vector 
ccr41al1 + CDC13-EST2 
rad271el1 + vector 
rad27tel1 + CDC13-EST2 
rad261el1 + vector 
rad26tel1 + CDC13-EST2 
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FIGURE 13. MMS SENSITIVITY WITH OR WITHOUT THE CDC13-EST2 FUSION CONSTRUCT. 
0.01% MMS 
Strains containing either an empty vector or a CDC13-EST2 fusion plasmid were cultured in selective 
media, serially diluted and spotted onto YEPD+/- MMS plates. An asterisk indicates that 0.005% 
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FIGURE 14. SUPPRESSION OF MMS SENSITIVITY IN RAD24-d TEL1-d AND RAD17-d TEL1-d BY A CDC13-EST2 
FUSION PLASMID. 
(A) & (B) Strains of the indicated genotype were transformed either with an empty vector or 
with a CDC13-ESn fusion plasmid (pVL1107) and screened for MMS sensitivity by colony-
forming assay on MMS plates. Error bars represent the standard deviation of values from three 
independent transformants. (C) Telomere lengths for tell-L1 interactions with or without the 
CDC13-EST2 fusion plasmid. Cells with the CDC13-EST2 fusion plasmid or empty vector were 
propagated on -Leu media and diluted into fresh rich medium overnight. Genomic DNA was 
harvested the following day and analyzed by electrophoresis and Southern blotting. The blot 
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FIGURE 15. HO-INDUCED TRANSLOCATION FREQUENCY FOR TEL1-d INTERACTIONS. 
1.0E-04 
NHEJ-mediated translocation frequency for tell-iJ double mutants following GAL-HO induction of 
double strand breaks on Ch V and Ch VII. Frequencies are measured as the fraction of colonies that 
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FIGURE 16. GROSS CHROMOSOMAL REARRANGEMENT (GCR) FREQUENCY IN 0.003% MMS. 
(A) GCR frequency for tell-,1 interactions. Strains were grown in YEPD + 0.003% MMS for 15 hours 
and subsequently plated on C-Arg-Ser + Canavanine + 5-FOA to simultaneously select for the loss of 
CANl and URA3 markers on the left end of chromosome V. Error bars represent standard deviations 
from two independent cultures per strain, each plated two times. The rad27-,1 mutants are plotted 
separately due to scale. (B) Gross chromosomal rearrangement (GCR) frequency in 0.003% MMS 
with or without the CDC13-EST2 fusion plasmid. The indicated strains containing either an empty 
vector (black bars) or the CDC13-EST2 fusion (grey bars) were grown in YEPD + 0.003% MMS for 15 
hours and subsequently plated on C-Arg-Ser + Canavanine + 5-FOA to select for simultaneous loss 
of CANl and URA3 markers. Error bars represent standard deviations from two independent 
cultures per strain, each plated two times. 
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T wildtype 0 mM HU 
~,,-", 
I wt 50 mM HU 
wt 150 mM HU 
tel1·jj 0 mM HU 
tel1·jj 50 mM HU 
tel1·jj 150 mM HU 
o 0.015% 0.03% 
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FIGURE 17. MMS SENSITIVITY FOLLOWING PRETREATMENT WITH HYDROXYUREA. 
The indicated strains were grown in the presence of the indicated dose of hydroxyurea for 4 hours 
to deplete nucleotide pools. Cells were then washed 2x and plated on MMS plates to assay MMS 
sensitivity by colony forming assay. The error bars indicate the standard deviation of values from 
three independent cultures. 
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CHAPTER 4: Conclusions and future directions 
The genesis of the reasoning that led to the yeast TEL 1 interaction screen and my 
characterization of the relationship between short telomeres and MMS sensitivity had its 
surprising beginning in a human microarray study. In this study, we found that A TM-/-
lymphoblast cells exhibited a robust transcriptional response to 5 Gy of IR that was 
indistinguishable from A TM+/+ cells (Chapter 2). Moreover, we detected radiation-
ind uced S 15 phosphorylation (an A TM target site) of the TP53 transcription factor in A TM-
/- cells, and this phosphorylation was significantly reduced upon treatment with the 
phosphoinositide 3-kinase related kinase (PIKK) inhibitor caffeine (Figure 1). These data 
are consistent with the overlap in substrate specificity for PIKKs (ABRAHAM 2001) and 
point to a model in which other PIKKs buffer the loss of A TM in the DNA damage 
response. A clear analog for this in Saccharomyces cerevisiae is the well-characterized 
interaction between TEL 1 and MEC1, in which loss of both PIKKs leads to synergistic 
DNA damage sensitivity and a progressive loss of telomere protection (CRAVEN et al. 
2002; MORROW et a/. 1995; RITCHIE et al. 1999; SANCHEZ et al. 1996). My intellectual 
curiosity led me to ask what other genetic mutations may cause an interaction effect with 
teI1-11 in response to DNA damage, and I began the large-scale screening for teI1-11 
interactions with some trepidation that TEL 1 interaction effects may not extend past its 
redundancy with MEC1. This turned out to not be the case however, as a diverse set of 
thirteen mutants conferred an increase in MMS and/or IR sensitivity with teI1-11 (Figures 
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6 and 7). The connection between MMS sensitivity and short telomeres for many of the 
tel1-11 xxx-11 interactions (Figure 11) and the inability of teI1-11 cells to deal with replication 
stress (Figure 17) suggest a novel and complex role for Tel1p in the DNA damage 
response that could be further elucidated by future experiments (Figure 18 and see 
below). 
A significant conclusion of this work is that I have shown in two different genetic 
contexts (via progressive shortening in tlc1 cells and via the CDC13-EST2-reversible 9-
1-1-11 teI1-11 interaction) that MMS sensitivity is telomere-length dependent. 
Characterization of the mechanism(s) underlying this connection will be an important 
direction for future studies. One possible (and testable) mechanism for the MMS 
sensitivity exhibited by 9-1-1-11 teI1-11 is that this phenotype results from a loss of telomere 
protection rendering ends susceptible to detection by DNA repair enzymes (Figure 18). 
In this case, MMS sensitivity may result from the sequestration of DNA repair enzymes 
at telomeres (and away from MMS-induced lesions elsewhere in the genome) or may be 
due to the fusion of unprotected telomeres with MMS-induced DSBs. The former case 
has been observed for post-senescent yeast telomeres maintained by recombination (LIN 
et al. 2009) however it is important to note that 9-1-1-11 teI1-11 telomeres are short but 
stably maintained (Figure 12). To test this model, ChiP could be used to measure the 
binding of DNA repair proteins to telomeres in 9-1-1-11 teI1-11 cells. The alternative model 
(increased fusion of telomeres to DSBs in 9-1-1-11 teI1-11) could be tested using the HO-
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inducible telomere capping assay (DuBoIs et al. 2002) that has been modified for the 
detection of telomere-DSB fusions (CHAN and BLACKBURN 2003). 
IN 
As much of the DNA damage sensitivity observed for teI1-iJ. xxx-iJ. interactions 
could not be suppressed by CDC13-EST2-mediated elongation of telomeres (Figures 13 
& 14), I propose that a general increase in replication stress may underlie the DNA 
damage sensitivity of a number of teI1-iJ. xxx-iJ. mutants (Figure 18). This is supported by 
the fact that a teI1-iJ. strain (and not wild-type) is rendered sensitive to MMS by pre-
depletion of nucleotide pools via hydroxyurea treatment (Figure 17). The mechanism for 
this is unclear and further studies may focus on elucidating the role of Tel1 p in preventing 
replication stress. One possibility is that teI1-iJ. combined with other mutations (ccr4-iJ., 
rad24-iJ. etc.) leads to a synergistic decrease in dNTP pools, an idea that is supported by 
the fact that Mec1!TeI1-mediated phosphorylation targets multiple ribonucleotide 
reductase inhibitors for degradation in response to DNA damage (HUANG et al. 1998; 
ZHAO and ROTHSTEIN 2002). Thus one prediction is that deletion of one or multiple RNR 
inhibitors (SML 1, CRT1) or overexpression of RNR3 (DESANY et al. 1998) may suppress 
the MMS sensitivity of teI1-iJ. xxx-iJ. double-mutants. Moreover, chromatographic 
separation and detection (i.e. via HPLC) could be used to directly assess whether levels 
of dNTPs are significantly reduced in teI1-iJ. xxx-iJ. strains (FASULLO et al. 2010). 
An alternative hypothesis is that Tel1 p may prevent replication fork collapse in 
response to MMS treatment, and an increase in fork stalling (via the identified interacting 
mutants) may increase the importance of Tel1 p's role here. Doksani et al. has previously 
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shown that in teI1-fJ. cells, a terminal replication fork (a fork encountering a DNA break or 
chromosome end) exhibits an increased tendency to revert into a cruciform structure, a 
precursor to fork collapse (DOKSANI et aJ. 2009). The combination of MMS treatment 
added to a preexisting state of replication stress may serve to increase the probability of 
these events. Such structures in MMS-treated teI1-fJ. xxx-fJ. strains could be detected by 
20 gel electrophoresis (BREWER and FANGMAN 1987). In addition, the observation that 
teI1-fJ. is required for terminal fork integrity suggests that these events could occur 
specifically or predominantly at telomeres (DOKSANI et al. 2009). The location of such 
events could be mapped using the recently developed strategy of Break-chip (FENG et aJ. 
2011), which involves labeling of broken DNA ends from intact chromosomal DNA 
preparations and hybridization to a microarray. Alternately, ChiP-chip or ChiP-Seq could 
be performed via the immunoprecipitation of a double-strand-break-associated protein 
(Rad52p for example) in order to determine whether DNA damage in MMS-treated tel1-
fJ. xxx-fJ. occurs in a site-specific manner. 
In addition, it would be worthwhile to ask whether a novel molecular function of 
Tel1p contributes to MMS resistance. This could be assessed by verifying that the MMS-
sensitive interactions we see for teI1-fJ. can be recapitulated with a kinase-dead form of 
Tel1p (MALLORY and PETES 2000). Moreover, as Tel1p binding at DNA ends occurs via 
an interaction with the MRX complex (NAKADA et al. 2003) it would be worthwhile to ask 
which (if any) of the thirteen genes identified in the teI1-fJ. screen also exhibit an interaction 
effect with an MRX mutant such as xrs2-fJ.. 
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One possible future direction for this project is the assessment of whether the tel1-
Ll gene-gene interactions observed in yeast can be recapitulated in human cells. The 
identification of novel A TM interactions in human cells may offer significant predictive and 
therapeutic potential. For example, as discussed in Chapter 2, the functionality of the 
DNA damage response (i.e. the radiation-induced gene set) is a strong predictor of breast 
tumor outcome (Table 2 and Figure 3), and the ability to search for ATM-interacting alleles 
in breast cancer GWAS data may result in the identification of novel risk factors for breast 
cancer development and/or outcome. 
Thus, follow-up studies may ask whether knockdowns of human orthologs of the 
13 tel1-Ll interactions confer MMS sensitivity with A TM depletion. One strategy would be 
to combine treatment with the specific ATM inhibitor KU55933 (HICKSON et al. 2004) with 
siRNA-mediated knockdowns of additional targets such as 9-1-1 components followed by 
testing for MMS sensitivity. Intriguingly, a recent study found that the specific combination 
of KU55933 combined with a telomerase inhibitor rendered MCF-7 tumor cells extremely 
sensitive to the chemotherapy agent etoposide (TAMAKAWA et al. 2010), suggesting that 
such a strategy may be feasible. However, as these techniques result in transient gene 
inhibition, and we expect that in at least a subset of cases the MMS-sensitivity is partly 
telomere-length dependent, generation of A TM-/- XXX-/- double-mutant cell lines may be 
necessary to observe an MMS-dependent interaction. Such a line might be generated 
utilizing recently developed genome editing strategies (TALENs, etc.) (JOUNG and 
SANDER 2013) in a cell line derived from an AT patient. Testing for conservation of these 
interactions in mammalian cells may give some indication of the utility of yeast-based 
DNA damage interaction screens for mapping out the mammalian interactome. 
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FIGURE 18. A MODEL FOR TEL1p/ ATM-MEDIATED SUPPRESSION OF MMS SENSITIVITY. 
The results of the tell-L1 interaction screen suggest a model in which Tellp suppresses DNA 
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